Methods of treatment with LOU064
The selective BTK inhibitor, LOU064, effectively prevents IgE-induced allergic reactions by inhibiting mast cell activation, offering a safer and more effective long-term treatment than existing BTK inhibitors, with minimal side effects and rapid onset.
Patent Information
- Application Number
- JP2023539015
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-07-21
- Filing Date
- 2022-12-12
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-12-12
AI Technical Summary
Current treatments for IgE-induced allergic reactions, such as anaphylaxis, are inadequate, with no effective prevention methods and existing BTK inhibitors posing safety concerns for long-term use, particularly in non-malignant indications and pediatric populations.
Development of a selective and reversible BTK inhibitor, LOU064, for the treatment and prevention of IgE-induced allergic reactions, offering safer and more effective long-term solutions compared to existing BTK inhibitors, with potential for use in combination therapies and oral administration.
LOU064 demonstrates rapid and sustained inhibition of allergic responses, reducing wheal size and mast cell activation, and provides long-term safety with minimal side effects, making it suitable for chronic use in treating food, drug, or poison allergic reactions.
Smart Images

Figure 0007594124000013 
Figure 0007594124000014 
Figure 0007594124000015
Abstract
Description
[Technical field]
[0001] The present invention relates to a BTK inhibitor, such as LOU064, or a pharma- ceutically acceptable salt or polymorph thereof, for use in the effective suppression of IgE-induced allergic responses to one or more allergens. [Background technology]
[0002] Food allergy affects millions of people of all ages in every country, and the rapidly increasing prevalence suggests that it is a newly emerging public health priority (Warren et al. 2020). The underlying cause of food allergy involves an immune mechanism in which allergen-specific IgE is synthesized in response to allergen exposure and binds to high affinity receptors for IgE (FcεRI receptors) via its Fc region on the surface membrane of mast cells and basophils (Sampson et al. 2006). Food allergy affects nearly 10% of people worldwide, and consistent epidemiological trends have been observed across North America, Europe, Asia, and Australia; the most common allergens are peanuts, nuts, seafood, eggs, milk, wheat, soy, and seeds (Warren et al. 2020, Sicherer and Sampson 2017). Allergies to peanuts, nuts, and seafood are usually lifelong (Jones and Burks 2017, Sicherer and Sampson 2017). Furthermore, one-third to one-half of food allergy sufferers, including adults, are likely allergic to two or more foods (Gupta et al 2011, Gupta et al 2019). Anaphylaxis is a potentially life-threatening systemic allergic reaction to a substance, such as a food, drug, or stinging insect venom. Despite efforts to alleviate allergies to these substances using immunotherapy, the incidence of anaphylaxis is increasing (Lieberman P.et al.,Ann Allergy Asthma Immunol.2006;97(5):596-602). Unfortunately, it is often fatal, even with immediate comprehensive medical treatment (J.Allergy Clin.Immunol.2020;145(4):1082). There are no known treatments that can prevent IgE-mediated anaphylaxis.
[0003] The IgE pathway plays a central role in the pathogenesis of most allergic diseases, including food allergies, drug allergies, allergic rhinitis, asthma, and chronic urticaria. When allergen-specific IgE binds to an allergen and crosslinks high affinity receptors (FcεRI) on the surface of mast cells and basophils, the activated signaling cascade leads to the release of many allergic mediators, including histamine, prostaglandins, leukotrienes, and cytokines, which are involved in eliciting the signs and symptoms.
[0004] To date, treatment of allergic diseases has relied heavily on blockade of specific mediators (eg, with antihistamines or leukotriene receptor antagonists) and / or broad immunosuppression with corticosteroids.
[0005] Currently, there is no effective treatment that can prevent anaphylaxis, and the mainstay of treatment is prevention by avoiding triggers. However, especially in the case of food allergies, strict avoidance is not always possible, so the standard treatment consists of early detection of signs and symptoms and the use of epinephrine injected intramuscularly after a reaction occurs. In contrast, there are situations in which patients are intentionally exposed to allergens, such as during skin testing, allergen immunotherapy (IT), and drug desensitization (all procedures carry the risk of severe systemic reactions). Desensitization to allergens, such as food allergens or drugs, is costly and laborious, as they typically require hospitalization of patients due to the risk of potentially life-threatening reactions.
[0006] There are several immunotherapies that have been tested for food allergy, such as oral immunotherapy (OIT), sublingual immunotherapy (SLIT), transdermal immunotherapy (EPIT), and OIT combined with anti-IgE monoclonal antibody (omalizumab). However, efficacy and safety have only been demonstrated in one Phase III study for peanut allergy. Furthermore, there have only been three randomized controlled trials of omalizumab-OIT combinations, and these are low-powered single-center studies; in these studies, the evidence level was low. Studies with long-term follow-up observations are rare, and therefore, clinical tolerability is unclear and remains unknown (Shoichiro T et al. EMJ. 2019; 4[4]: 63-70).
[0007] Currently, there is only one oral immunotherapy (OIT) approved for peanut allergy sufferers (Palforzia™).
[0008] BTK is an essential kinase for signaling through FcεRI in human mast cells and basophils. Because it is also important for B cell maturation, BTK has been pharmacologically targeted for the treatment of B cell malignancies. There are currently three FDA-approved BTK inhibitors (BTKis) in the United States. Ibrutinib (trade name Imbruvica®; Pharmacyclics, and AbbVie), acalabrutinib (Calquence®; Acerta and AstraZeneca), and zanubrutinib (Brukinsa®; BeiGene) are all oral covalent small molecule inhibitors of BTK.
[0009] In addition, several BTK inhibitors (BTKis) are in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE). For example, acalabrutinib and zanubrutinib, as well as novel compounds ONO-4059 (tirabrutinib), HM71224 (posertinib), and ABBV-105 (upadacitinib) are currently being tested for their efficacy in B-cell malignancies and / or autoimmune diseases such as RA, Sjögren's syndrome (SjS), and SLE. In addition, evobrutinib, trebrutinib, and fenebrutinib have entered phase III trials in MS patients, olebrutinib has been tested in phase II trials, and BIIB091 has been tested in phase I trials for efficacy in treating MS.
[0010] Studies have also demonstrated the ability of ibrutinib to reduce or eliminate skin prick test reactivity to aeroallergens and foods in allergic patients (Dispenza et al. J. Allergy Clin Immunol. 2018;141(5):1914-1916.e7) and skin tests returned to baseline 1 week after ibrutinib cessation, suggesting a short duration of efficacy (2021). However, it is unclear whether the inhibitory effects seen in the skin prick test translate to inhibitory effects in organs other than the skin. The penetration of BTKis into various tissues where mast cells reside is unknown. Although ibrutinib has been demonstrated to have rapid efficacy in preventing IgE-mediated activation of circulating basophils, it is unclear whether BTKis can sufficiently inhibit IgE-mediated activation of tissue-resident mast cells in multiple organs such as the lungs, skin, and gastrointestinal tract.
[0011] Despite suggestions that BTK inhibitors may be used to prevent and / or treat allergic reactions to plants, BTK inhibitors have not yet been shown to suppress clinically relevant allergic reactions and / or prevent anaphylaxis in humans. Although acalabrutinib is currently in Phase II trials in the prevention of allergic reactions to peanut allergens in adults with peanut allergy, no clinical efficacy data have been reported to date for BTK inhibitors related to food allergy.
[0012] Furthermore, due to the lack of selectivity of some earlier developed BTK inhibitors (e.g., acalabrutinib, ibrutinib), they may not be suitable for the treatment of indications requiring long-term / chronic and safe use, particularly in pediatric or adolescent populations, and / or for non-malignant indications. The most common side effects of currently approved BTK inhibitors include nausea, diarrhea, rash, infection, cytopenia, bleeding, and arrhythmias. In particular, the long-term toxicity profile of ibrutinib, a first-in-class inhibitor, is well characterized and includes clinically significant occurrences of arrhythmias, bleeding, infection, diarrhea, arthralgia, and hypertension. Acalabrutinib, an early second-generation BTKi to gain approval from the US Food and Drug Administration, demonstrates improved kinase selectivity for BTK, but is associated with commonly observed adverse reactions including infections, headache, and diarrhea (Hematology Am Soc Hematol Educ Program. 2020 Dec 4; 2020(1):336-345).
[0013] Long-term safety data are not available for BTK inhibitors currently in development, but the available safety data for fenebrutinib may suggest that the biggest obstacle BTK inhibitors may face is whether side effects during chronic use are tolerable. For example, the primary event noted in the Phase IIa study of fenebrutinib was a transient grade 3 increase in ALT and / or AST in 8.3% and 6.3% of subjects in the high-dose treatment arm. Some of the side effects already observed for some BTKis may limit their use to treat or prevent non-malignant indications, especially if long-term administration may be required. Furthermore, none of the FDA-approved BTK inhibitors have been approved in children and adolescents. Thus, until safety data in children are available, it is unclear whether BTK inhibitors are a viable option for use in treating or preventing IgE-induced allergic reactions in children.
[0014] Because of the increasing prevalence (including allergies to multiple foods), current limited treatment options, potentially life-threatening consequences, inability of food avoidance alone to confer protection, and often lifelong burden of disease, there is a great medical need to develop new, safer treatments for food allergies. [Brief description of the drawings]
[0015] [Figure 1] Passive cutaneous anaphylaxis (PCA) in mice: LOU064 inhibits skin edema. [Diagram 2] BTK occupancy in the spleen of BALB / c mice 2.5 hours after administration. [Diagram 3] Reverse passive Arthus (RPA) response in mouse skin: LOU064 inhibits skin swelling. [Figure 4] BTK occupancy in the spleen of C57B16 mice 5 hours after administration. [Diagram 5] Time-dependent pharmacological effects of LOU064 on skin swelling. [Figure 6]Comparison of time-dependent BTK occupancy in spleen and lung upon pharmacological inhibition of skin swelling following a single dose of 30 mg / kg LOU064. [Figure 7] Effects on total number of cells in bronchoalveolar lavage fluid (BALF) after treatment with LOU064 (10 mg / Kg and 30 mg / kg, orally (po), twice daily (bid)) or vehicle (10 mL / Kg, orally (po), twice daily (bid)) in sensitized mice challenged with 1% w / v OVA or saline (aerosol, days 21-24) and with PBS at 16 hours and PBS at 16 hours (intrathecal (it) groups 1 and 2) or polyinosinic-polycytidylic acid (Poly I:C 100 μg / animal, intrathecal (it)). BALF was collected 24 hours after OVA challenge. [Figure 8] Effects on the number of eosinophils in bronchoalveolar lavage fluid (BALF) after treatment with LOU064 (10 mg / Kg and 30 mg / kg, orally (po), twice daily (bid)) or vehicle (10 mL / Kg, orally (po), twice daily (bid)) in sensitized mice challenged with 1% w / v OVA or saline (aerosol, days 21-24) and with PBS at 16 hours and PBS at 16 hours (intrathecal (it) groups 1 and 2) or polyinosinic-polycytidylic acid (Poly I:C 100 μg / animal, intrathecal (it)). BALF was collected 24 hours after OVA challenge. [Figure 9] Effects on the number of neutrophils in bronchoalveolar lavage fluid (BALF) after treatment with LOU064 (10 mg / kg and 30 mg / kg, orally (po), twice daily (bid)) or vehicle (10 mL / Kg, orally (po), twice daily (bid)) in sensitized mice challenged with 1% w / v OVA or saline (aerosol, days 21-24) and PBS at 16 hours and PBS at 16 hours (intrathecal (it) groups 1 and 2) or polyinosinic-polycytidylic acid (Poly I:C 100 μg / animal, intrathecal (it)). BALF was collected 24 hours after OVA challenge. [Figure 10]Effects on the number of macrophages in bronchoalveolar lavage fluid (BALF) after treatment with LOU064 (10 mg / kg and 30 mg / kg, orally (po), twice daily (bid)) or vehicle (10 mL / Kg, orally (po), twice daily (bid)) in sensitized mice challenged with 1% w / v OVA or saline (aerosol, days 21-24) and PBS at 16 hours and PBS at 16 hours (intrathecal (it) groups 1 and 2) or polyinosinic-polycytidylic acid (Poly I:C 100 μg / animal, intrathecal (it)). BALF was collected 24 hours after OVA challenge. [Figure 11] Effects on the number of lymphocytes in bronchoalveolar lavage fluid (BALF) after treatment with LOU064 (10 mg / Kg and 30 mg / kg, orally (po), twice daily (bid) or vehicle (10 mL / Kg, orally (po), twice daily (bid)) in sensitized mice challenged with 1% w / v OVA or saline (aerosol, days 21-24) and with PBS at 16 hours and PBS at 16 hours (intrathecal (it) groups 1 and 2) or polyinosinic-polycytidylic acid (Poly I:C 100 μg / animal, intrathecal (it)). BALF was collected 24 hours after OVA challenge. [Figure 12] Favorable particle size distribution of nano-sized LOU064. [Figure 13] Simulation of splenic BTK occupancy at steady state. [Figure 14] (A) 24-hour trough of BTK occupancy at steady state, with median predictions as points and vertical lines showing 95% prediction intervals. (B) 24-hour average of BTK occupancy at steady state, with median predictions as points and vertical lines showing 95% prediction intervals. Summary of the Invention
[0016] The problem underlying the present invention is to provide a safe and effective treatment or a safe and effective prevention of IgE-induced allergic reactions, such as food, drug or toxin allergy reactions, in particular IgE-induced allergic reactions to one or more allergens, such as food allergens, more in particular, for example, IgE-induced anaphylactic reactions. In particular, it is an object of the present invention to provide a safe and effective long-term treatment or prevention of IgE-induced food allergic reactions, such as anaphylactic reactions.
[0017] Thus, the present invention relates to BTK inhibitors, e.g., reversible or irreversible BTK inhibitors, for use in the treatment and / or prevention of IgE-induced allergic reactions, e.g., food, drug, or toxin allergic reactions, more particularly, food allergic reactions. In particular, the present invention relates to selective BTK inhibitors that are safe and suitable for long-term use (i.e., chronic use) in the treatment and / or prevention of IgE-induced allergic reactions, e.g., food, drug, or toxin allergic reactions, more particularly, food allergic reactions. Particularly useful in the present invention are BTK inhibitors that are selective for BTK over tec (e.g., at least 10-fold, at least 20-fold, at least 30-fold BTK / Tec selectivity).
[0018] Another object of the present invention is to provide an improved treatment and / or prevention of IgE-induced allergic reactions, such as food, drug, or poison allergic reactions, more particularly food allergic reactions. One aspect of the present invention is to provide an improved prevention of IgE-induced anaphylaxis, e.g., induced by one or a mixture of food allergens. For example, one object of the present invention is to provide a treatment or prevention of IgE-induced allergies that is more effective and / or safer than treatment with other BTK inhibitors (e.g., less selective BTK inhibitors), in particular more effective and / or safer than treatment with acalabrutinib or ibrutinib. Also, one object of the present invention is to provide a treatment and / or prevention of IgE-induced allergic reactions, in particular food allergic reactions, that is more effective, safer and / or more convenient than treatment with anti-IgE monoclonal therapy. In particular, it is an object of the present invention to provide treatment and / or prevention of IgE-induced allergic reactions that has a faster onset of action (e.g., less than 4 weeks, less than 2 weeks, or less than 1 week) compared to anti-IgE monoclonal therapies, which take 8-12 weeks to act, and to provide a treatment that is more conveniently administered at home and does not require the use of a medical facility.
[0019] Thus, disclosed herein is a method for preventing or treating an IgE induced allergic reaction, such as a food, drug, or toxin allergic reaction, such as an anaphylactic reaction, more particularly a method for preventing or treating an IgE induced allergic reaction to one or more food allergens (e.g., peanuts, tree nuts, milk, wheat, soy, egg, sesame, seafood, or mixtures thereof), comprising administering a therapeutically effective dose of LOU064 to a subject in need thereof.
[0020] Another aspect of the present invention relates to an irreversible BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for treating or preventing an IgE-induced food allergic reaction to one or more allergens (e.g., food allergens such as peanuts, nuts, milk, wheat, soy, egg, sesame, seafood, or mixtures thereof), preferably for preventing an IgE-induced food allergic reaction to one or more allergens.
[0021] A further subject of the invention is a process for the manufacture of a medicament for use in the abovementioned treatment.
[0022] Further aspects, advantageous features and preferred embodiments of the present invention, summarized in the following embodiments E1 to E39, each alone or in combination, serve to solve the object of the present invention:
[0023] E1. A method of treating or preventing an IgE-induced allergic reaction to one or more allergens (e.g., drug, toxin, or food allergens) in a subject in need thereof, comprising administering to the patient a therapeutically effective dose of a selective BTK inhibitor, e.g., LOU064.
[0024] E2. The method of E1, wherein the one or more allergens includes or is a food allergen.
[0025] E3. The method of E2, wherein the food allergen is selected from peanuts, tree nuts, milk, wheat, egg, soybean, sesame, seafood, in particular peanuts.
[0026] The method of E1, E2 or E3, wherein the therapeutically effective dose of LOU064 is from about 20 mg to about 200 mg daily.
[0027] E5. The method of E4, wherein the therapeutically effective dose of LOU064 is from about 10 mg twice a day to about 100 mg twice a day.
[0028] E6. The method of E5, wherein the therapeutically effective dose of LOU064 is about 10 mg twice daily.
[0029] E7. The method of E5, wherein the therapeutically effective dose of LOU064 is about 25 mg twice daily.
[0030] E8. The method of E5, wherein the therapeutically effective dose of LOU064 is about 100 mg twice daily.
[0031] The method of any one of E1 to E8, wherein LOU064 is administered over a short period of time, such as less than 6 months, preferably less than 3 months or less than 1 month.
[0032] E10. The method according to E9, wherein LOU064 is administered for up to 18 weeks, such as for 4, 10, 12, 16 or 18 weeks.
[0033] The method according to any one of E1 to E8, wherein LOU064 is administered for an extended period of time, such as for more than 6 months, such as for a year, preferably for more than a year.
[0034] The method according to any one of E1 to E11, wherein LOU064 is administered as a monotherapy.
[0035] The method according to any one of E1 to E12, wherein LOU064 is not administered simultaneously with a strong inhibitor of CYP3A, such as a strong inhibitor of CYP3A4.
[0036] The method according to any one of E1-E11 and E13, wherein LOU064 is co-administered with a therapeutic agent.
[0037] E15. The method of E14, wherein LOU064 is co-administered with a corticosteroid and / or an immunosuppressant (e.g. an inhaled corticosteroid), a leukotriene receptor antagonist (LTRA), a short-acting beta agonist (SABA) or a long-acting beta agonist (LABA).
[0038] E16. The method of any one of claims E1-E11 and E13, wherein LOU064 is co-administered with oral immunotherapy (OIT), sublingual immunotherapy (SLIT), transdermal immunotherapy (EPIT), preferably OIT.
[0039] E17. The method according to E16, wherein LOU064 is an adjunct to oral immunotherapy (OIT), sublingual immunotherapy (SLIT), transdermal immunotherapy (EPIT), preferably OIT.
[0040] E18. The method according to E16 or E17, wherein the oral immunotherapy is a peanut protein (e.g. Palforzia).
[0041] E19. The method according to any one of E16 to E18, wherein LOU064 is administered starting at least 2 days (e.g. at least 2-14 days) prior to administration of the oral immunotherapy.
[0042] E20. The method of E19, wherein LOU064 is administered during the escalation phase of the immunotherapy treatment.
[0043] E21. The method according to any one of E1-E20, wherein the method is prevention of an IgE-induced allergic reaction.
[0044] E22. The method of any one of E1-E21 for preventing anaphylaxis following accidental exposure to any allergen or mixture thereof (e.g. food allergens).
[0045] The method according to E21 or E22, wherein LOU064 achieves maximum prevention after a minimum of 2 days (eg 2-14 days, preferably 2-7 days) of treatment.
[0046] E24. The patient meets the following criteria: (a) Male and female patients, aged 2 years and older (e.g., 2–5 years, or 6–11 years, 12–17 years, or 18–55 years); (b) a confirmed history of allergies to foods, including but not limited to peanuts, tree nuts, wheat, eggs, milk, soybeans, and seafood; (c) positive allergen-specific IgE (e.g., peanut sIgE ≥ 6 kUA / L at screening); and (d) a positive skin prick test to an allergen to which the patient is allergic (e.g., defined as a wheal with a mean diameter (longest diameter and midpoint perpendicular diameter) of ≥ 4 mm compared with a negative control); The method according to any one of E1 to E23, selected according to one or more of:
[0047] E25. The method according to any of E1-E24, wherein the patient is an adult patient (18 years or older) or an adolescent (12-17 years old).
[0048] E26. The method according to any of E1-E24, wherein the patient is a child aged between 2 and 11 years, such as between 2 and 5 years or between 6 and 11 years.
[0049] E27. At least one of the following applies: After up to 4 weeks (e.g., after 1 week, or after 2 weeks, or after 3 weeks, or after 4 weeks) of treatment with LOU064, At least 90% of treated patients do not exhibit an allergic reaction upon a food challenge of 600 mg of peanut protein; b. At least 90% of treated patients do not exhibit an allergic reaction upon a food challenge of 1000 mg of peanut protein; c. The method of any one of E1-E26, wherein at least 80% of treated patients do not exhibit an allergic reaction upon a food challenge of 3000 mg of peanut protein.
[0050] E28. The method of any one of E1-E27, wherein the patient achieves a reduction from baseline in the FAQLQ total domain score of between 0.45 and 0.5.
[0051] E29. The method of any one of E1-E28, wherein the patient achieves a reduction from baseline in the total domain score FAIM.
[0052] E30. The method of any one of E1-E29, wherein the observed difference in response rate between treated and untreated patients in a double-blind, placebo-controlled food challenge of 600 mg of allergen (e.g., peanut allergen) is greater than 35%, where the response rate is defined as less than or equal to a mild response to a 600 mg oral food challenge.
[0053] E31. The method of any one of E1-E30, wherein by week 12 or week 24 of treatment, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipase do not change by more than 10% compared to baseline levels at the start of treatment.
[0054] The method according to any one of E1-E31, wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising nano-sized particles of LOU064.
[0055] The method according to any one of E1 to E32, wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising nano-sized particles of LOU064 having an average particle size of from about 50 nm to about 750 nm as measured by PCS.
[0056] The method according to any one of E1-E33, wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064 and a binder in a weight ratio of about 2:1.
[0057] The method of any one of E1-E34, wherein LOU064 is administered in a suitable oral pharmaceutical formulation comprising LOU064, a binder and a surfactant in a weight ratio of about 2:1:0.08.
[0058] The method according to any one of E1-E33, wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064 and a binder in a weight ratio of about 1:1.
[0059] The method of any of E1-E33 and E36, wherein LOU064 is administered in a suitable oral pharmaceutical formulation comprising LOU064, a binder and a surfactant in a weight ratio of about 1:1:0.05.
[0060] The method according to any one of E1-E37, wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064, polyvinylpyrrolidone-vinyl acetate copolymer as a binder and sodium lauryl sulfate as a surfactant.
[0061] When E39.LOU064 is measured at a temperature of about 25°C and an X-ray wavelength, λ, of 1.5405 Å, the following peaks are observed: 7.8±0.2°2θ, 9.2±0.2°2θ, 12.0±0.2°2θ, 13.6±0.2°2θ, 15.6±0.2°2θ, 16.0±0.2°2θ, 17.8±0.2°2θ, 18.3±0.2°2θ, 18.7±0.2°2θ, 19.2±0.2°2θ, 19.9±0.2°2θ, 22.1± E39. The method of any of E1-E38, wherein the crystalline form of the anhydrous free base is characterized by an X-ray powder diffraction pattern comprising one or more representative peaks for 2θ selected from the group consisting of 0.2 degrees 2θ, 23.4±0.2 degrees 2θ, 23.9±0.2 degrees 2θ, 24.8±0.2 degrees 2θ, 25.2±0.2 degrees 2θ, 25.5±0.2 degrees 2θ, 27.2±0.2 degrees 2θ, and 29.6±0.2 degrees 2θ. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0062] definition As used herein, Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase and a member of the TEC kinase family. BTK is expressed in selected cells of the adaptive and innate immune system, including B cells, macrophages, mast cells / basophils, and platelets. BTK is essential for signaling through Fcε receptors (FcεR1 for IgE) and activating Fcγ receptors (FcγR for IgG), as well as the B cell antigen receptor (BCR) and BTK inhibitors. BTK inhibitors such as ibrutinib have been approved for the treatment of B cell malignancies (Hendriks et al., 2014). Recently, it has been demonstrated that inhibition of BTK results in inhibition of mast cell and basophil activation / degranulation in vitro and a reduction in wheal size in skin prick tests by patients with IgE-mediated allergies (Smiljkovic et al., 2017; Regan et al., 2017; Dispenza et al., 2018). Therefore, inhibition of BTK is an attractive therapeutic concept for treating various autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, chronic urticaria, atopic dermatitis, asthma, and primary Sjögren's syndrome (Tan et al. 2013; Whang and Chang 2014). Examples of BTK inhibitors include non-covalent, reversible BTK inhibitors such as fenebrutinib, and non-covalent, irreversible inhibitors of BTK, such as evobrutinib, trebrutinib, rilzabrutinib, tirabrutinib, branebrutinib, orelabrutinib, and remibrutinib (LOU064).
[0063] As used herein, IgE refers to immunoglobulin E.
[0064] The term "comprising" encompasses "including" as well as "consisting", e.g., a composition "comprising" X may consist only of X or may include something additional, e.g., X+Y.
[0065] The term "about" in reference to a numerical value x means, for example, + / - 10%. When used before a numerical range or list of numerical values, the term "about" applies to each numerical value in the series, e.g., the phrase "about 1 to 5" should be interpreted as "about 1 to about 5", or, for example, the phrase "about 1, 2, 3, 4" should be interpreted as "about 1, about 2, about 3, about 4, etc."
[0066] As used herein, the phrase "pharmacologically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, consistent with a reasonable benefit / risk ratio, and within the scope of sound medical judgment.
[0067] The term "salt" or "salts" refers to an acid addition salt of a compound of the present invention. "Salt" specifically includes "pharmaceutically acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compound of the present invention and are typically not biologically or otherwise harmful. In many cases, the compounds of the present invention are capable of forming acid salts due to the presence of an amino group thereon. Examples of salts are those disclosed in WO 2020 / 234779 and WO 2015 / 079417, which are incorporated herein by reference.
[0068] As used herein, the term "polymorph" refers to a crystalline form having the same chemical composition but different spatial arrangement of the molecules, atoms, and / or ions that form the crystal. Crystalline forms of LOU064 are disclosed in WO2020 / 234779, which is incorporated herein by reference.
[0069] The term "administering" in reference to a compound, for example, LOU064, is used to refer to the delivery of that compound to a subject by any route, preferably oral administration.
[0070] As used herein, the term "therapeutically effective amount or dose" of a compound of the present disclosure (i.e., a compound of Formula (I) or a pharma- ceutically acceptable salt or polymorph thereof) refers to an amount of a compound of the present disclosure that induces a biological or medical response in a subject (a target patient), such as a decrease or inhibition of an enzyme or protein activity, or improves symptoms, alleviates a pathological condition, slows or delays disease progression, or prevents a disease. The therapeutically effective dosage of a compound, pharmaceutical composition, or combination thereof depends on the patient's species, weight, age, sex, and individual condition, disorder or disease being treated or its severity. The frequency of administration varies depending on the compound used and the particular condition being treated or prevented.
[0071] As used herein, the term "pharmaceutical acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and the like, and combinations thereof, as known to those skilled in the art (see, e.g., Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
[0072] The term "treatment" or "treating" is defined herein as the application or administration of a BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising LOU064 or a pharma- ceutically acceptable salt thereof, to a subject (preferably a human) or a tissue or cell line isolated from a subject, where the subject has a particular disease (e.g., IgE-induced food allergy), a symptom associated with the disease (e.g., an IgE-induced food allergic reaction), or a predisposition to developing the disease (if applicable), with the purpose of curing one or more symptoms of the disease (if applicable), reducing the severity, alleviating, ameliorating such symptoms, ameliorating the disease, reducing or ameliorating any associated symptoms of the disease or predisposition to developing the disease. The term "treatment" or "treating" includes treating subjects suspected of having a disease as well as subjects who are ill or have been diagnosed as suffering from a disease or condition.
[0073] As used herein, the terms "prevention", "prevent" and "preventing" of a disease or disorder (IgE-induced food allergy) refer to prophylactic treatment of a disease or disorder; or delaying and / or inhibiting the onset or progression of a disease or disorder (e.g. inhibiting an IgE-induced food allergic reaction). The term "prevention" refers to reducing sensitivity to an allergen in a patient subject (i.e. increasing the threshold of sensitivity to an allergen as assessed by oral food challenge) to an allergic reaction to said allergen. This term includes, for example, reducing food allergy reactions upon oral exposure to a known allergen (e.g. food allergen) by a minimum of 80% from baseline (e.g. 85%, 90% from baseline). This term also includes protection from potentially life-threatening IgE-induced allergic reactions and more particularly IgE-induced anaphylaxis.
[0074] As used herein, the term "anaphylaxis" is defined in accordance with the World Allergy Organization Guidance 2020 as a severe, life-threatening, systemic hypersensitivity reaction characterized by rapid onset with potentially life-threatening airway, respiratory, or circulatory system involvement, usually, but not necessarily, accompanied by skin and mucosal changes. A wide variety of molecules can induce anaphylaxis. These are the most common proteins that induce anaphylaxis in an IgE-dependent manner or molecules that directly activate mast cells. IgE-mediated anaphylaxis is caused by the interaction of an allergen (usually a protein) with an allergen-specific IgE / high affinity receptor (FcεRI) complex expressed in effector cells, primarily mast cells and basophils.
[0075] As used herein, the phrase "population of subjects" is used to mean a group of subjects.
[0076] As used herein, the term "subject" refers to an animal. Typically, an animal is a mammal. A subject also refers to, for example, a primate (e.g., a human, male or female), cow, sheep, goat, horse, dog, cat, rabbit, rat, mouse, fish, bird, etc. In certain embodiments, the subject is a primate. In preferred embodiments, the subject is a human. The term "subject" is used synonymously with "patient" when it refers to a human.
[0077] As used herein, a subject is "in need of" treatment or prevention if such subject would benefit biologically, medically, or in quality of life from the treatment.
[0078] In certain embodiments of the disclosed methods, a BTK inhibitor, such as LOU064, or a pharma- ceutically acceptable salt thereof, is used to treat a population of subjects having an IgE-induced food allergic reaction to one or more allergens.
[0079] As defined herein, the terms "IgE-induced allergy (or allergic reaction) to one or more allergens" or "IgE-mediated allergy (or allergic reaction)" are used interchangeably and refer to, for example, drug allergy, poison allergy or food allergy (or allergic reaction), preferably an allergic reaction to food allergens such as peanuts, nuts, milk, wheat, soybean, egg, sesame, seafood or mixtures thereof. In certain embodiments, food allergy also refers to the indications for the prevention of allergic reactions, including anaphylaxis, following accidental exposure to food allergens, for example in adult and pediatric patients aged 2 years or older with a confirmed or suspected diagnosis of IgE-induced food allergy to one or more allergens. The term "IgE-induced food allergic reaction" refers to an adverse reaction to food, which is caused by an unregulated type 2 immune response.
[0080] In one embodiment, drug allergy refers to the indication for the prevention of allergic reactions, including anaphylaxis, following exposure to drug allergens, e.g., in adult and pediatric patients 2 years of age or older, with a confirmed or suspected diagnosis of IgE-induced allergy to one or more allergens.
[0081] IgE-mediated reactions are usually divided into immediate-onset reactions (occurring up to 2 hours after food ingestion) and immediate plus late (immediate-onset symptoms followed by prolonged or persistent symptoms). IgE-mediated drug- or food-related reactions include skin symptoms (e.g., angioedema, acute urticaria); gastrointestinal reactions (symptoms may include itching and swelling of the lips, tongue and palate, laryngeal edema, nausea, abdominal cramps, vomiting and diarrhea); respiratory reactions (e.g., allergic rhinitis conjunctivitis and bronchoconstriction); and systemic reactions (rapidly progressive anaphylaxis, a multi-organ system reaction that is typically combined with gastrointestinal (GI) or respiratory symptoms and includes cardiovascular collapse).
[0082] A non-responder to treatment with a BTK inhibitor, e.g., LOU064 or a pharma- ceutically acceptable salt thereof, is defined as a subject who fails to achieve at least 80% improvement from baseline or has a worsening of symptoms. A responder to treatment with LOU064 or a pharma- ceutically acceptable salt thereof is defined as a subject who achieves a minimum of 80% improvement from baseline.
[0083] The term "oral immunotherapy" or "OIT" is a treatment in which allergic patients gradually take increasing amounts of the allergen to which they are allergic (e.g., food allergens) over a period of months in order to induce a safer immune response to said allergen and to induce some degree of desensitization. OIT therapy consists of two phases: 1. a titration phase, which consists of slowly increasing the amount of allergen - this phase can take many months; and 2. a maintenance phase, in which the patient maintains the same dose. Unfortunately, the titration phase presents a risk of severe allergic reactions, including anaphylaxis. Patients who are able to reach a maintenance dose are generally protected from reactions resulting from accidental exposure as long as they take OIT.
[0084] The term "sublingual immunotherapy" or SLIT is another form of allergy immunotherapy that involves administering allergens under the tongue, typically daily. Currently, the only form of SLIT approved by the FDA is a tablet for ragweed, northern grasses such as timothy grass, and dust mites. The tablet is placed under the tongue for 1-2 minutes and then swallowed when it dissolves. This process is repeated 3 days a week to daily. The tablet builds tolerance to pollen and reduces symptoms over time. For continued effectiveness, treatment may be required for 3 years or more. Allergy tablets are currently available for ragweed and grass pollen only.
[0085] The term "transdermal immunotherapy" or EPIT is another form of allergen immunotherapy that consists in delivering allergens by repeated application to the skin. EPIT uses patches and aims to produce sustained sensitization or tolerance by continuous (and constant) allergen exposure to the skin.
[0086] As used herein, "selecting" and "selected" in relation to a patient are used to mean that a particular patient is specifically selected from a larger group of patients based on (by) the particular patient having a certain criterion. Similarly, "selectively treating" or "selectively preventing" refers to providing treatment or prevention to a patient with a particular disease (e.g., a patient known or suspected to have an allergic reaction to a particular food allergen), where the patient is specifically selected from a larger group of patients based on (by) the particular patient having a certain criterion. Similarly, "selectively administering" refers to administering a drug to a patient who is specifically selected from a larger group of patients based on (by) the particular patient having a certain criterion. "Selecting", "selectively treating" and "selectively administering" mean that a standard treatment plan is delivered based solely on the patient's membership in a larger group, but rather that an individualized treatment is delivered to the patient based on the patient's medical history (e.g., previous therapeutic interventions, e.g., previous treatment with a biologic), biology (e.g., specific genetic markers), and / or symptoms (e.g., failure to meet certain diagnostic criteria). As used herein, in the context of the method of treatment, selecting refers not to the accidental treatment of a patient with a certain criterion, but to the deliberate selection of administering treatment to a patient based on the patient having a certain criterion.Therefore, selective treatment / administration differs from standard treatment / administration, which delivers a certain drug to all patients with a certain disease, regardless of the patient's medical history, disease symptoms, and / or biology.In some embodiments, a patient is selected for treatment based on having a known allergic reaction to exposure to a food allergen.
[0087] The term "pharmaceutical combination" as used herein means a product resulting from the use of two or more active ingredients or from mixing or combining them. It should be understood that pharmaceutical combination as used herein includes both fixed and non-fixed combinations of active ingredients. The term "fixed combination" means that the active ingredients, e.g., a compound of formula (I) or its pharmaceutically acceptable salt or polymorphs, and one or more combination partners are administered to a patient simultaneously as a single entity or dosage form. In such cases, the term refers to a fixed-dose combination in one unit dosage form (e.g., capsule, tablet, or sachet). The term "non-fixed combination" or "kit of parts" both mean that the active ingredients, e.g., a compound of the present disclosure and one or more combination partners and / or one or more auxiliary agents, are administered or co-administered to a patient independently as separate entities, either simultaneously, in parallel or sequentially, without specific time limitations, such administration providing therapeutically effective levels of the two compounds in the patient's body, especially when these time intervals allow the combination partners to exhibit a joint effect, e.g., additive or synergistic effect. The term "non-fixed combination" also applies to cocktail therapy, e.g., the administration of three or more active ingredients. Thus, the term "non-fixed combination" defines, among other things, an administration, use, composition or formulation, in the sense that the compounds described herein can be administered independently of each other, i.e., at the same time or at different times. It should be understood that the term "non-fixed combination" also encompasses the use of a single agent, e.g., LOU064 or a pharma- ceutically acceptable salt or polymorph thereof, together with one or more fixed combination products with each independent formulation containing different amounts of the active ingredients therein. It is to be further understood that the combination products described herein, as well as the term "non-fixed combination", encompass the active ingredients (including the compounds described herein) and the combination partners are administered as completely separate pharmaceutical dosage forms or formulations that may even be sold independently of each other.Instructions for use of the non-fixed combination are or may be provided in the packaging, e.g., leaflets, etc., or other information provided to the physician and / or medical staff. In this case, the independent formulations or parts of the formulations, products, or compositions may be administered simultaneously or staggered, i.e., each individual part of the kit of parts may be administered at different time points and / or at equal or different time intervals for any part of the kit of parts. In particular, the time intervals of administration are selected such that the effect on the disease being treated by the combined use of the parts is greater / higher than the effect obtained by the use of the compound of formula (I) or its pharma- ceutically acceptable salt or polymorph alone; thus, the compounds used in the pharmaceutical combinations described herein are jointly active. The ratio of the total amount of the compound of formula (I) or its pharma- ceutically acceptable salt or polymorph to the second drug administered as a pharmaceutical combination may be altered or adjusted to better suit the needs of the particular patient subpopulation being treated, or the needs of a single patient, which may depend, for example, on the patient's age, sex, weight, etc.
[0088] As used herein, terms such as "co-administration" or "administration in combination" are meant to encompass the administration of one or more compounds described herein together with a selected combination partner to a single subject (e.g., a patient or subject) in need thereof, and are intended to include treatment regimens in which the compounds are not necessarily administered by the same route of administration and / or at the same time.
[0089] The term "adjuvant" or "adjuvant therapy" or "adjuvant therapy" refers to a therapy given in addition to a primary or initial therapy to maximize efficacy and improve safety. In the context of the present invention, adjuvant therapy is the use of a BTK inhibitor (e.g., LOU064) in addition to a primary therapy of oral immunotherapy (OIT). For example, the adjuvant therapy (i.e., BTK inhibitor or LOU064) is given prior to the main treatment (e.g., OIT) and during the titration phase of OIT to prevent allergic and / or anaphylactic reactions during the titration phase.
[0090] LOU064 LOU064 (=N-(3-(6-amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, INN: remibrutinib) is disclosed in WO 2015 / 079417 A1 as a drug candidate for the selective inhibition of Bruton's tyrosine kinase. The compound is a potent, highly selective, irreversible covalent BTK inhibitor. By binding to the inactive conformation of BTK, LOU064 exhibits superior kinase selectivity, thus reducing kinase off-target binding, and through covalent inhibition, the compound exhibits potent and sustained pharmacodynamic effects without the need for prolonged, high systemic compound exposure (Angst, D. et al., Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase, J Med Chem. 2020 May 28;63(10):5102-5118).
[0091] LOU064 for use in the methods of the present invention has the formula (I): [ka] It is a free base represented by:
[0092] In other embodiments, N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide is the anhydrous crystalline form A of the free base, as disclosed in WO 2020 / 234779 (Example 1), which is incorporated herein by reference.
[0093] LOU064, which has already been proposed for use in the treatment of chronic spontaneous urticaria (CSU) (WO 2020 / 234782 A1) and Sjögren's syndrome (SjS) (WO 2020 / 234781 A1), is currently being tested in clinical trials for SjS (Phase 2); CSU and MS (Phase 3).
[0094] In WO 2020 / 234782 A1, it was generally suggested that doses of 10 mg, 25 mg and 100 mg administered twice a day (bid) achieve maximal efficacy in CSU.
[0095] In a phase 2b, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of remibrutinib over 12 weeks in patients with at least moderately active CSU and inadequate control with H1-antihistamines, patients received remibrutinib 10 mg qd (once daily), 35 mg qd, 100 mg qd, 10 mg bid (twice daily), 25 mg bid, 100 mg bid, or placebo (1:1:1:1:1:1:1 ratio). The 25 mg bid regimen was found to be particularly effective.
[0096] BTK occupancy in blood and / or tissues has been reported to be a suitable biomarker for selecting doses for clinical trials such as CSU and SjS studies (WO 2020 / 234782 and WO 2020 / 234781).
[0097] Furthermore, it has been reported that BTK occupancy and persistence of BTK occupancy differ in the blood and various tissues of female rats (WO 2020 / 234781).
[0098] BTK occupancy in different tissues is related to efficacy and optimal dose selection in different indications. However, there is currently no consensus on all tissues related to multiple allergic reactions caused by food allergy, and therefore tissues that need to be infiltrated to treat or prevent IgE-induced food allergic reactions. As reported in rats, BTK occupancy and BTK occupancy half-life are different in blood and various tissues.
[0099] Furthermore, BTK occupancy half-life depends on the turnover rate (the ability of the BTK protein in the cell to regenerate). Such turnover rate varies in each tissue and is species-specific. BTK occupancy further depends on the PK / PD properties of the compound, which are also species-specific.
[0100] Therefore, clinical response in an oral food challenge cannot be predicted using the CSU dose or any dose disclosed for other indications.
[0101] Pharmaceutical compositions for use in the methods of the present invention The BTK inhibitor, i.e., the compound of formula (I), or a pharma- ceutically acceptable salt or polymorph thereof, when combined with a pharma- ceutically acceptable carrier, can be used as a pharmaceutical composition. Such compositions can contain, in addition to the compound of formula (I), or a pharma- ceutically acceptable salt or polymorph thereof, carriers, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials known in the art. The characteristics of the carrier depend on the route of administration. The pharmaceutical composition for use in the disclosed method can also contain additional therapeutic agents for the treatment of a particular targeted disorder. For example, the pharmaceutical composition can also include an anti-inflammatory or antipruritic agent. Such additional factors and / or agents can be included in the pharmaceutical composition to produce a synergistic effect with the compound of formula (I), or a pharma- ceutically acceptable salt or polymorph thereof, or to minimize side effects caused by the compound of formula (I), or a pharma- ceutically acceptable salt or polymorph thereof. In a preferred embodiment, the pharmaceutical composition for use in the disclosed methods comprises a compound of formula (I) or a pharma- ceutically acceptable salt or polymorph thereof in a dose of about 10 mg, about 20 mg, about 25 mg, about 50 mg, or about 100 mg, preferably about 25 mg, about 50 mg, or about 100 mg.
[0102] Suitable compositions for oral administration include an effective amount of the compounds of the present invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweeteners, flavoring agents, coloring agents, and preservatives to provide pharma-ceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with non-toxic pharma-ceutically acceptable excipients suitable for the manufacture of tablets. These excipients are, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binders, for example, starch, gelatin or acacia; and lubricants, for example, magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the digestive tract, thereby providing sustained activity over a longer period of time.For example, time-delay materials such as glyceryl monostearate or glyceryl distearate can be used.Oral preparations can be provided as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
[0103] Pharmaceutical compositions for use in the disclosed methods can be prepared in a conventional manner. In one embodiment, the pharmaceutical composition is provided for oral administration. For example, the pharmaceutical composition can be a) diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants, such as silica, talcum, stearic acid, its magnesium or calcium salts and / or polyethylene glycol; further for tablets c) binders, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone; optionally d) disintegrants, such as starch, agar, alginic acid or its sodium salt, or effervescent mixtures; and / or e) Absorbents, colouring agents, flavourings and sweeteners It is a tablet or gelatin capsule containing the active ingredient together with
[0104] Thus, pharmaceutical compositions for use in the methods of the invention comprise LOU064 and one or more pharma- ceutically acceptable carriers, each of which is independently selected from a filler, a lubricant, a binder, a disintegrant, and a glidant.
[0105] In another embodiment, suitable pharmaceutical composition, LOU064 may be present in any pharma- ceutically acceptable form. The pharmaceutical composition may preferably be in tablet or capsule form. Tablets may be film-coated or enteric-coated according to methods known in the art. It may also be preferred to include LOU064 in the pharmaceutical composition / formulation as nano- or micro-sized particles.
[0106] When LOU064 is present in the pharmaceutical formulation in the form of nano-sized particles, the average particle size may be less than 1000 nm. Preferably, the average particle size of LOU064 may be less than 500 nm, more preferably less than 250 nm.
[0107] In a preferred embodiment, the average particle size of LOU064 can be about 50 nm to about 1000 nm, or about 50 nm to about 750 nm, or about 60 nm to about 500 nm, or about 70 nm to about 350 nm, or about 100 nm to about 170 nm, more preferably, the average particle size of LOU064 can be about 100 nm to about 350 nm, or about 110 nm to about 200 nm, or about 120 nm to about 180 nm, or about 120 nm to about 160 nm, preferably, the average particle size of LOU064 can be about 150 nm to about 200 nm.
[0108] When LOU064 is present in the pharmaceutical formulation in the form of nano-sized particles, oral administration is preferably at a dose of about 50 mg to about 150 mg twice daily, more preferably at a dose of about 100 mg twice daily.
[0109] When LOU064 is present in the pharmaceutical formulation in the form of micro-sized particles, the average particle size may be 1-5 μm, or preferably 1.0-1.5 μm. Preferably, the average particle size of LOU064 may be 1.1-1.3 μm.
[0110] When LOU064 is present in the pharmaceutical formulation in the form of micro-sized particles, oral administration is preferably at a dose of about 100 mg to about 300 mg twice daily, for example at a dose of about 100 mg twice daily.
[0111] In a preferred embodiment, the polydispersity index (PI) is from 0.01 to 0.5, more preferably from 0.1 to 0.2, in particular from 0.12 to 0.14. A preferred particle size distribution is shown in FIG.
[0112] The above average particle size is weighted by intensity. The average particle size can be determined by dynamic light scattering. Preferably, the average particle size is determined by photon correlation spectroscopy (PCS). In particular, the device "Zetasizer Nano ZS", Version 7.13, manufactured by Malvern Panalytical Ltd. (UK) can be used to determine the average particle size.
[0113] Preferably, the measurement is carried out as a wet dispersion method using a 0.1 mM NaCl solution in purified water (1:10), where the attenuator index is between 2 and 9, in particular 5. The measurement is preferably carried out at 25° C. Further preferred settings of the measurement system are as follows: Cell: Disposable sizing cuvette Count rate (kcPs): 315 Duration: 60 seconds Measurement position (mm): 4.65.
[0114] In one embodiment of the invention, the LOU064 composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for oral administration to human beings. Typically, compositions for oral administration are capsules or tablets.
[0115] In one embodiment, the formulation for LOU064 is formulated according to the formulations disclosed in U.S. Provisional Patent Application No. 63 / 141558 or family members thereof (e.g., WO 2022 / 162513), which are incorporated by reference herein.
[0116] According to the present invention, a suitable pharmaceutical composition for oral administration comprises LOU064 and a binder.
[0117] Suitable binders include polyvinylpyrrolidone-vinyl acetate copolymer, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hypromellose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, polyethylene glycol, polyvinyl alcohol, shellac, polyvinyl alcohol-polyethylene glycol copolymer, polyethylene-propylene glycol copolymer, or mixtures thereof. Preferably, the binder is polyvinylpyrrolidone-vinyl acetate copolymer.
[0118] The weight ratio of LOU064 to the binder can be from about 3:1 to about 1:3; for example, about 3:1, about 2:1, about 1:1, and preferably, the weight ratio of LOU064 to the binder is about 2:1 or about 1:1.
[0119] Preferably, a pharmaceutical composition suitable for oral administration comprises LOU064, a binder and a surfactant.
[0120] Suitable surfactants include sodium lauryl sulfate, potassium lauryl sulfate, ammonium lauryl sulfate, sodium lauryl ether sulfate, polysorbates, perfluorobutane sulfonate, dioctyl sulfosuccinate, or mixtures thereof. Preferably, the surfactant is sodium lauryl sulfate.
[0121] The weight ratio of LOU064, binder and surfactant is about 2:1:0.5, or about 2:1:0.1, or about 2:1:0.08, or about 2:1:0.05, or about 2:1:0.04, or about 2:1:0.03, or about 2:1:0.02. Preferably, the weight ratio of LOU064, binder and surfactant is about 2:1:0.08 or about 1:1:0.05.
[0122] In a particularly preferred embodiment, a suitable pharmaceutical composition for oral administration comprises LOU064, a binder and a surfactant, wherein the binder is polyvinylpyrrolidone-vinyl acetate copolymer (copovidone) and the surfactant is sodium lauryl sulfate (SLS), and the weight ratio of LOU064, copovidone and SLS is about 2:1:0.08. It is further particularly preferred that LOU064 is present in this pharmaceutical composition in the form of nano-sized particles, preferably having an average particle size of about 100 nm to about 200 nm as measured by PCS.
[0123] A method of treatment or prevention using LOU064, or a pharma- ceutically acceptable salt thereof, or a crystalline form thereof. Disclosed herein are methods and BTK inhibitors, e.g., irreversible BTK inhibitors, e.g., a compound of formula (I) (i.e., LOU064) or a pharma- ceutically acceptable salt or polymorph thereof, for use in preventing, treating or modifying the course of an IgE-induced allergic reaction to one or more allergens, e.g., toxins, drugs or foods, e.g., peanut, in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of LOU064 or a pharma- ceutically acceptable salt thereof. In one aspect of this embodiment, the invention relates to LOU064 or a pharma- ceutically acceptable salt thereof for use in preventing an IgE-induced food allergic reaction to one or more allergens, e.g., peanut, in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of LOU064 or a pharma- ceutically acceptable salt thereof. LOU064 for use in the disclosed methods may be incorporated into a pharmaceutical composition, as described above, and administered in vivo to treat a toxin, drug or food allergic patient (i.e., a human patient).
[0124] For example, an IgE-induced food allergy reaction to one or more allergens is a food allergy reaction, such as a peanut allergy reaction.
[0125] In yet another example, an IgE-induced food allergic reaction disease or disorder to one or more allergens refers to peanut, nut, milk, wheat, soy, egg, sesame, seafood allergy reactions.
[0126] In another embodiment, the subject suffers from a food allergy, eg, a peanut allergy.
[0127] The ability of LOU064 to inhibit defined allergen responses was evaluated by skin prick testing (SPT) in healthy atopic subjects in the multiple ascending dose (MAD) study part of a first-in-human study. SPTs with seven allergens (grass pollen mix, birch pollen, alder pollen, hazel pollen, house dust mite, cat dander, and horse dander) were performed before any dose (baseline) and at different time points after the first dose and after 11 days of once-daily dosing. The study demonstrated a dose-dependent reduction in wheal size up to a dose of 100 mg. Above 100 mg, no dose-dependent trend was evident, but the highest reduction was observed at the highest dose tested (600 mg qd). Across all trials, participants showed an average reduction in wheal size of 3 mm at doses of 100 mg qd. or higher (Kaul et al. Clin. Transl. Sci. 2021;14(5),pp 1756-1768).
[0128] Dose-dependent inhibition of FcεR1-mediated basophil activation was also demonstrated with LOU064 during first-in-human studies. In a single ascending dose study (SAD) of LOU064, ex vivo blood basophil activation as measured by CD63 was nearly completely inhibited (>89%) at the 60 mg dose, reaching nearly 100% inhibition at higher doses 24 hours after dosing. Doses of 100 mg and above demonstrated near complete inhibition. In contrast, another basophil activation marker, CD203c+, showed a maximum of 79.4% inhibition at 8 hours in the 200 mg cohort. In a multiple ascending dose study (MAD), complete inhibition of blood basophil activation as measured by CD63 expression was achieved over the entire treatment period (days 1-12) and beyond with daily doses of LOU064 of 50 mg or greater. Trough level inhibition of CD63 on the last day of dosing was 80% at the lowest tested dose of 10 mg.qd (once daily); this was more potent at either higher dose. Dose-dependent inhibition was observed for the CD63 marker, reaching trough inhibition of >97% at 100 mg qd and above at the last day of dosing. Inhibition of CD203c+ basophils was highest at 400 mg qd and 200 mg bid, at 63% and 67%, respectively (Kaul et al. Clin. Transl. Sci. 2021;14(5),pp 1756-1768).
[0129] Furthermore, the inventors demonstrated that treatment with LOU064 (10 mg / kg, 30 mg / Kg) significantly reduced the number of cells involved in pulmonary anaphylaxis (eosinophils, basophils, macrophages and lymphocytes) in an ovalbumin-induced anaphylaxis mouse model (Example 3). Based on those results and the translation model between animals and humans (Journal of basic and clinical pharmacy, 7(2), 27-31), the calculated human equivalent dose (HED) for 30 mg / kg corresponds to approximately 170 mg for a 70 kg person, and the calculated human equivalent dose (HED) for the lowest effective dose of 10 mg / kg corresponds to approximately 56 mg for a 70 kg person (Nair, AB, & Jacob, S. (2016).
[0130] Finally, an in-house predictive model of splenic BTK occupancy in humans (Example 7) showed that twice-daily (bid) dosing was more effective than QD dosing at the same dose for achieving higher BTK occupancy (Figure 13). Thus, a dose of 25 mg bid of LOU064 is the minimum human effective dose, and a dose of 100 mg bid is also shown to be effective in humans.
[0131] The appropriate dosage will vary depending, for example, on the particular pharma- ceutically acceptable salt of LOU064, the particular polymorphic form of LOU064, the host, the mode of administration, the pharmaceutical composition, and the nature and severity of the condition being treated, as well as the nature of prior treatments the subject has undergone.
[0132] In a preferred embodiment, LOU064 may be administered regardless of body weight, sex, age, or race. For example, a 35-year-old woman weighing 60 kg is preferably administered the same dose as a 50-year-old man weighing 90 kg. In particular, body weight, sex, age, or race have no clinically significant effect on the pharmacokinetics of LOU064.
[0133] Ultimately, the attending medical professional will decide the amount of LOU064 with which to treat each individual subject, in one embodiment, the attending medical professional may administer a low dose of LOU064 and observe the subject's response.
[0134] In one embodiment of the present disclosure, LOU064 or a pharma- ceutically acceptable salt thereof is orally administered at a dose of about 20 mg to about 200 mg daily.
[0135] In another embodiment, LOU064 or a pharma- ceutically acceptable salt thereof is administered at a dose of about 25 mg daily, or about 50 mg daily, or about 75 mg daily, or about 100 mg daily. In one aspect of this embodiment, LOU064 is administered at a dose of about 25 mg QD (once a day), or about 50 mg QD, or about 75 mg QD, or about 100 mg QD.
[0136] In one embodiment of the disclosure, LOU064 or a pharma- ceutically acceptable salt thereof is administered orally at a dose of about 10 mg twice daily to about 100 mg twice daily, for example, about 10 mg twice daily (BID), about 25 mg BID, about 50 mg BID, or about 100 mg BID.
[0137] In another embodiment, LOU064 is administered orally at a dose of about 10 mg twice daily.
[0138] In another embodiment, LOU064 is administered orally at a dose of about 25 mg twice daily.
[0139] In another embodiment, LOU064 is administered orally at a dose of about 50 mg twice daily.
[0140] In another embodiment, LOU064 is administered orally at a dose of about 75 mg twice daily.
[0141] In another embodiment, LOU064 is administered orally at a dose of about 100 mg twice daily.
[0142] The duration of treatment using the pharmaceutical composition of the present disclosure will vary depending on the severity of the disease or disorder being treated and the condition and personal response of each individual subject.In some embodiments, the subject is administered LOU064 for a short period of time, for example, up to 4 weeks, for example, up to 6 weeks, for example, up to 8 weeks, for example, up to 10 weeks, for example, up to 12 weeks.LOU064 can be administered for a short period of time, for example, as defined herein above, to prevent severe food allergy reactions, for example, during business trips and / or vacations, and avoidance of triggers, any other situation where exposure to allergens is not adequately controlled.
[0143] In one embodiment, LOU064 is administered at least 2 days prior to potential risk of exposure to an allergen (e.g., a food allergen). In another embodiment, LOU064 is administered within at least 1 week prior to potential risk of exposure to an allergen (e.g., a food allergen), such as 1 week, 2 weeks, 3 weeks, or 4 weeks. The advantage of LOU064 over anti-IgE therapy is its fast onset of action to achieve maximum protection / prevention of allergic reactions.
[0144] In certain other embodiments, the subject is administered LOU064 for an extended period of time (e.g., LOU064 is used indefinitely for as long as the disease is present to justify its use, e.g., at least 6 months, e.g., at least 10 months, e.g., 1 year, e.g., 1 year, 2 years, 3 years, 4 years, more than 10 years total. LOU064 or a pharmaceutically acceptable salt thereof may be used for up to 2 years, 5 years, 10 years, 15 years, 20 years, or lifelong. In certain embodiments, treatment with LOU064 is a chronic treatment.
[0145] In practicing some of the disclosed methods of treatment or use, a therapeutically effective dose of LOU064 or a pharma- ceutically acceptable salt thereof is administered to a subject, e.g., a mammal (e.g., a human). While it is understood that the disclosed methods provide for the treatment or prevention of an IgE-induced food allergic reaction using LOU064 or a salt thereof, this does not mean that the treatment is necessarily a monotherapy.
[0146] In one embodiment of the invention, a BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, is administered to a subject as monotherapy.
[0147] In another embodiment of the invention, a BTK inhibitor, such as an irreversible BTK inhibitor, such as LOU064, is administered to a subject as a combination therapy.
[0148] Indeed, if a subject is selected for treatment with LOU064, LOU064 may be administered according to the methods of the disclosure in combination with other agents and therapies for treating a subject suffering from a disease or disorder involving IgE, e.g., in combination with at least one additional therapeutic agent, e.g., an anti-IgE antibody (e.g., omalizumab or ligelizumab), a corticosteroid or an immunosuppressant, e.g., a systemic corticosteroid or an immunosuppressant.
[0149] In some embodiments of the disclosed uses, methods, and kits, the subject has an IgE-induced allergic reaction to one or more allergens, where the allergen is a drug or food, such as a food, such as peanut. In some embodiments, the subject may also have asthma and / or urticaria, such as a disease or disorder selected from asthma, allergic asthma, rhinitis, allergic rhinitis, urticaria, and CSU. In some embodiments of the disclosed uses, methods, and kits, the subject has an IgE-induced food allergy reaction to one or more allergens (e.g., food allergens such as peanut, nuts, milk, wheat, soybean, egg, sesame, seafood, or mixtures thereof).
[0150] In other embodiments of the disclosed uses, methods, and kits, the subject has an IgE-induced food allergic reaction to one or more allergens, where the allergen is a food, such as peanuts.
[0151] For example, this may be the case if the subject being treated is allergic, or if the subject also suffers from another disease or disorder selected from asthma, urticaria, and rhinitis, e.g., selected from allergic asthma, CSU, and allergic rhinitis.
[0152] When co-administered with one or more additional agents, LOU064 or a pharma- ceutically acceptable salt thereof may be administered simultaneously with the other agents, or sequentially. If administered sequentially, the attending physician will determine the appropriate sequence of administering LOU064 or a pharma- ceutically acceptable salt thereof in combination with the other agents and appropriate dosages for co-delivery.
[0153] A variety of therapies may be beneficially combined with the disclosed LOU064 in treating a disease or disorder involving IgE, as disclosed herein, including, for example, anti-IgE antibodies (e.g., omalizumab, ligelizumab), corticosteroids (e.g., inhaled or systemic corticosteroids), immunosuppressants, leukotriene receptor antagonists (LTRAs), short-acting beta agonists (SABAs), or long-acting beta agonists (LABAs).
[0154] In certain embodiments of the disclosed uses, methods, and kits, LOU064, or a pharma- ceutically acceptable salt thereof, may be prescribed as a first line treatment or added to either the standard of care.
[0155] In another embodiment, LOU064 or a pharma- ceutically acceptable salt may be administered according to the methods of the present disclosure in combination with other agents and therapies for treating IgE-induced food allergic reactions.
[0156] In one embodiment, LOU064 or a pharma- ceutically acceptable salt thereof is administered in conjunction with oral immunotherapy (OIT), sublingual immunotherapy (SLIT), transdermal immunotherapy (EPIT), preferably OIT. In one aspect of this embodiment, LOU064 is administered as an adjunct to OIT.
[0157] Oral immunotherapy (OIT) is a potential treatment for food allergy that involves increasing amounts of food allergens given under medical supervision. Such procedures result in desensitization to the allergen. OIT treatments are costly and laborious as they typically require hospitalization of the patient due to the risk of potentially life-threatening reactions.
[0158] In one embodiment, a BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, when administered according to the methods of the present disclosure, reduces the frequency and severity of side effects (e.g., severe systemic reactions, e.g., allergic reactions such as anaphylaxis) associated with OIT, SLIT, EPIT, preferably OIT.
[0159] In another embodiment, a BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, when administered according to the methods of the present disclosure, shortens the OIT titration (i.e., the titration phase of OIT), e.g., allowing more patients to successfully complete OIT.
[0160] In one embodiment, a BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, is administered as an adjunct to peanut protein OIT therapy.
[0161] To date, the single currently approved OIT product for reducing allergic reactions in peanut allergy patients is Palforzia™. Thus, a BTK inhibitor, such as an irreversible BTK inhibitor, such as LOU064t, can be administered according to the methods of the present disclosure as an adjunct to peanut protein (e.g., Palforzia™).
[0162] In one embodiment, a BTK inhibitor for use according to the methods described herein, e.g., an irreversible BTK inhibitor, e.g., LOU064, is administered beginning at least 2 days, or at least 1 week (7 days), or at least 2 weeks (14 days) prior to administration of the oral immunotherapy. In one aspect of this embodiment, a BTK inhibitor for use according to the methods described herein, e.g., an irreversible BTK inhibitor, preferably LOU064, is further administered during the titration phase of the immunotherapy treatment, after which LOU064 is discontinued at the start of the maintenance phase of OIT.
[0163] Patient Selection In one embodiment, the patient is an adult (18 years of age or older).
[0164] In another embodiment, the patient is an adolescent (ages 12-17).
[0165] In yet another embodiment, the patient is a pediatric patient (ages 2-11 or 6-11).
[0166] In another embodiment of the invention, patients receiving a BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, for the treatment or prevention of an IgE-induced food allergic reaction are selected according to the following criteria: a) Male and female patients, aged 2 years and older (e.g. 2-5 years or 6-11 years, 12-17 years or 18-55 years); b) a confirmed history of allergies to foods including, but not limited to, peanuts, tree nuts, wheat, eggs, milk, soy, and seafood; c) positive allergen-specific IgE (e.g., peanut sIgE ≥ 6 kUA / L at screening); d) A positive skin prick test to an allergen to which the patient is allergic (e.g., defined as a wheal with a mean diameter (longest diameter and midpoint perpendicular diameter) ≥ 4 mm compared to a negative control).
[0167] In one aspect of the above embodiments, the patient administered LOU064 or a pharma- ceutically acceptable salt thereof is not a patient with uncontrolled asthma, defined as having one of the following criteria: - Patient has a predicted normal FEV1 < 80% at the time of the first screening visit - One hospitalization for asthma within the 12 months prior to the screening visit.
[0168] Effectiveness In one embodiment, the invention relates to a BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, for use in any of the methods described herein, wherein the BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, achieves prevention at x weeks of treatment. In one aspect of this embodiment, prevention is defined as a minimum of 80% reduction from baseline, (e.g., a minimum of 85% reduction or a minimum of 90% reduction from baseline).
[0169] In one embodiment, the invention relates to a BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064, for use in the methods described herein, wherein at least one of the following is true: After up to 4 weeks (e.g., after 1 week, or after 2 weeks, or after 3 weeks, or after 4 weeks) of treatment with LOU064, - At least 90% of treated patients do not show an allergic reaction upon food challenge of 600 mg of food allergen (e.g. 600 mg peanut protein), - At least 90% of treated patients do not show an allergic reaction upon food challenge of 1000 mg of food allergen (e.g. 1000 mg of peanut protein), - At least 80% of treated patients do not exhibit an allergic reaction upon a food challenge of 3000 mg of food allergen (e.g. 3000 mg of peanut protein).
[0170] In another embodiment, the invention relates to LOU064 for use in the methods described herein, wherein the patient achieves a reduction from baseline in the FAQLQ total domain score of 0.45 to 0.5.
[0171] The Food Allergy Quality of Life Questionnaire (FALQLQ) is a disease-specific health-related quality of life (HRQoL) questionnaire for patients with food allergy. They have been developed and validated, including an adult questionnaire (AF), a child questionnaire (CF), and a teenager questionnaire (TF) as well as two questionnaires completed by parents of food-allergic children (Parent Questionnaire PF and Parent Questionnaire Teenager PFT). These questionnaires are reliable and valid instruments to measure the impact of food allergy on HRQoL. More specifically, the Food Allergy Quality of Life Questionnaire (FAQLQ) assesses the impact of food allergy on participants' HRQoL (i.e., domains consist of risk of accidental exposure, emotional effects, allergen avoidance, and dietary restrictions). The FAQLQ-Children's Questionnaire (8-12 years) (Flokstra-de Blok BM et al (2009) Clinical. Exp. Allergy;39:(1)127-37), the FAQLQ-Teenager's Questionnaire (13-17 years) (Flokstra-de Block BM et al. (2008) J. Allergy Clinical Immunology;122:139-44,144.e1-2) and the FAQLQ-Adult's Questionnaire (≥18 years) (Flokstra-de Blok BM et al (2009) Allergy;64(8):1209-17) are self-administered, validated food allergy-specific HRQoL questionnaires. The FAQLQ-Parent Questionnaire (FAQLQ-PF) is completed by parents of children aged 0-12 years with food allergies (Dunn Galvin et al (2008), Clin Exp Allergy, 40 (2010), 476-485).
[0172] The number of items and domains varies depending on the FAQLQ document administered. Each question is scored on a 7-point scale from 1 to 7 (i.e., "none" to "maximum" reduction in HRQoL, respectively). The total score is the arithmetic mean of all non-missing items. Domain scores are calculated similarly.
[0173] In yet another embodiment, the invention relates to LOU064 for use in the methods of the invention, wherein the patient achieves a reduction from baseline in the total domain score FAIM.
[0174] The Food Allergy Independent Measure (FAIM) is a valid and reliable instrument for measuring patient outcome prediction and has been developed for children (FAIM-CF), adolescents (FAIM TF) and adults (FAIM AF) (Flokstra-de Block et al. Allergy 65(5):630-5). The Food Allergy Independent Measure (FAIM) reflects the participant's perceived food allergy severity and food allergy-related risk. The FAIM contains four questions that are similarly scored from 0 to 6, with higher scores indicating a worse prediction of adverse outcomes (e.g., severe reactions or death) if the allergen is accidentally ingested.
[0175] In yet another embodiment, the invention relates to LOU064 for use in the methods described herein, wherein the observed difference in response rate between treated and untreated patients in a double-blind, placebo-controlled food challenge of 600 mg of allergen (e.g., peanut allergen) is greater than 35%, where the response rate is defined as less than or equal to a mild response to a 600 mg oral food challenge.
[0176] In a further embodiment, the invention relates to LOU064 for use in the methods described herein, wherein the patient does not have or has no more than a mild response to an oral food challenge (e.g., after receiving a dose of 600 mg allergen (e.g., peanut protein). A mild response is defined according to the Consortium for Food Allergy Research (CoFAR: Sampson HA et al. J. Allergy Clin. Immunol; 130(6):1260-74) to include one or more of the following: On the skin - limited (slight) or localized hives, swelling (e.g. mild lip edema), skin flushing (e.g. some areas of mild erythema) or mild itching (e.g. occasional scratching) Respiratory - rhinorrhea (e.g. occasional sniffling or sneezing), stuffy nose, occasional cough, sore throat GI - Mild abdominal discomfort (including mild nausea with or without decreased activity), isolated vomiting thought to be secondary to gagging.
[0177] In another embodiment, the invention relates to LOU064 for use in the methods described herein, in which the patient does not develop a moderate or severe reaction to an oral food challenge (e.g., after receiving a dose of 600 mg of allergen (e.g., peanut protein). A moderate reaction is defined according to the Consortium for Food Allergy Research (CoFAR: Sampson HA et al. J. Allergy Clin. Immunol; 130(6):1260-74) to include one or more of the following: Skin - generalized urticaria (e.g., many or widespread hives), swelling (e.g., significant lip or facial swelling), itching causing persistent scratching, several or more areas of erythema or marked erythema Respiratory - Throat tightness without hoarseness, persistent cough, wheezing without difficulty in breathing GI - Persistent moderate abdominal pain / cramps / nausea, vomiting with reduced activity
[0178] Severe reactions are defined according to the Consortium for Food Allergy Research (CoFAR: Sampson HA et al. J. Allergy Clin. Immunol;130(6):1260-74) as including one or more of the following: Skin - Severe generalized urticaria / angioedema / erythema Respiratory - laryngeal edema, throat tightness with hoarseness, wheezing with dyspnea, stridor GI - Severe abdominal pain / cramps / recurrent vomiting Nervous system - mental state changes · Circulatory system – clinically significant reduction in blood pressure
[0179] safety The short-term safety of LOU064 at single doses up to 600 mg and further at 100 mg bid for up to 18 days has been demonstrated in Phase I clinical trials, however, data relating to long-term safety are not currently available.
[0180] Considering the dose-limiting side effects observed with the covalent irreversible BTK inhibitors evobrutinib and trebrutinib, evobrutinib already exhibited dose-limiting liver enzyme elevations at a dose of 75 mg bid in Phase II clinical trials, and trebrutinib exhibited dose-limiting diarrhea (Becker A. et al., 2019, Clin Transl Sci; 13, 325-336; Montalban X. et al., 2019, N Engl J Med; 380(25):2406-17, Smith PF et al., 2019, ACTRIMS Forum, Feb 28, 2019, P072), it is encouraging that no significant increase in the occurrence of these adverse events was seen with LOU064, even at higher doses. We have demonstrated that LOU064 is safe, even at doses as high as 100 mg bid over extended periods (up to 52 weeks) (Example 14). Notably, LOU064 does not induce any dose-limiting liver enzyme elevations or other off-target effects at doses of 100 mg bid over long periods (up to 52 weeks), making it suitable for long-term treatment.
[0181] Thus, one object of the invention is LOU064 for use in the methods described, wherein by 12 weeks, by 24 weeks or by 52 weeks of treatment, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lipase levels do not change by more than 10% compared to baseline levels at the start of treatment.
[0182] Therefore, it was particularly surprising that LOU064 not only effectively prevents IgE-induced allergic reactions (e.g. food allergic reactions), but also has a better safety profile compared to other BTK inhibitors, especially compared to acalabrutinib, especially when treatment is maintained over a long period of time. For example, the BTK inhibitors currently approved primarily for the treatment of hematological malignancies (ibrutinib, acalabrutinib, and zanubrutinib) have known safety hazards. The major safety hazards include infections, effects on platelet function (risk of bleeding), and cytopenias. Other safety concerns for one or more of the approved BTKis include cardiac arrhythmias (atrial fibrillation and flutter) and, for ibrutinib only, heart failure and hypertension.
[0183] Thus, in a preferred embodiment of the present invention, LOU064 or a pharma- ceutically acceptable salt thereof for use in treating or preventing an IgE-induced allergic reaction (e.g., a food allergic reaction) is used for long-term treatment. The term long-term treatment indicates that LOU064 or a pharma- ceutically acceptable salt thereof is used for a long period of time. For example, LOU064 or a pharma- ceutically acceptable salt thereof may be safely used for more than 6 months, 10 months, 1 year, 2 years, 3 years, 4 years, 10 years. LOU064 or a pharma- ceutically acceptable salt thereof may be used for up to 2 years, 5 years, 10 years, 15 years, 20 years, or lifelong.
[0184] In one embodiment, LOU064 not only effectively prevents IgE-induced allergic reactions (e.g., food allergic reactions), but also exhibits the following characteristics: - no clinically relevant increase in risk of infection, - no clinically relevant increase in major bleeding; - No clinically relevant elevations in liver enzymes and have a safety profile that includes one or more of the following:
[0185] It is expected that LOU064 oral drug exposure may be increased several-fold when administered with a CYP3A inhibitor, particularly a strong CYP3A inhibitor, such as a strong CYP3A4 inhibitor. Similarly, a strong inducer of CYP4A, such as CYP3A4, may significantly reduce exposure, resulting in reduced efficacy of LOU064. These properties of LOU064 are relevant not only for the treatment and / or prevention of IgE-induced allergic reactions, but also for the treatment and / or prevention of any BTK-mediated pathology. A strong CYP3A inhibitor or CYP3A inducer is defined according to the FDA 2020 guidelines. Thus, a strong CYP3A inhibitor (e.g., a CYP3A4 inhibitor) is an inhibitor that, after co-administration with LOU064, results in a greater than 5-fold increase in area under the curve (AUC) or a greater than 80% decrease in clearance compared to administration of LOU064 alone. A strong CYP3A inducer (e.g., a strong CYP3A4 inducer) is an inducer that, following coadministration with LOU064, decreases the AUC by 80% or more (e.g., by 85%, by 90%, by 95%) compared to administration of LOU064 alone.
[0186] Coadministration with strong CYP3A inhibitors and / or inducers, such as strong CYP3A4 inhibitors and / or inducers, may possibly cause significant changes in LOU064 drug exposure and should be avoided. Strong CYP3A4 inhibitors include drugs selected from boceprevir, clarithromycin, cobicistat, conivaptan, danoprevir / ritonavir, darunavir / ritonavir, elvitegravir / ritonavir, idelalisib, indinavir, indinavir / ritonavir, itraconazole, ketoconazole, LCL161, lopinavir / ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, saquinavir / ritonavir, telaprevir, telithromycin, tipranavir / ritonavir, troleandomycin, Viekira pack or / and voriconazole. CYP3A4 inhibitors may also be found in grapefruit juice.
[0187] Thus, in another preferred embodiment, LOU064 is not administered concomitantly with strong inhibitors and / or inducers of CYP3A4, eg, as defined herein above.
[0188] It has further been found that LOU064 can be co-administered with oral contraceptives, such as ethinyl estradiol or levonorgestrel, without significant effects on their exposure and efficacy. Thus, in a preferred embodiment, LOU064 is co-administered with an oral contraceptive.
[0189] In a preferred embodiment, no premedication is administered prior to the first administration of LOU064.
[0190] As a covalent irreversible BTK inhibitor, LOU064 acts by irreversible inhibition of BTK, which is counterbalanced by de novo protein synthesis. Thus, without wishing to be bound by any theory, it is believed that while reconstitution of the B cell pool after B cell depletion may take months, restoration of B cell function after BTK inhibition may be achieved soon after cessation, particularly within a few days. Thus, if necessary, this therapy may be stopped quickly, thereby giving clinicians and patients the ability to respond more easily and faster if unforeseen circumstances arise.
[0191] In another embodiment, LOU064 is advantageously selected if the patient is scheduled to undergo chemotherapy within the next 12 months.
[0192] Especially in light of the COVID-19 pandemic, B cell depleted patients are at higher risk of infection, and the lack of a fully functional adaptive immune response is likely to lead to a more severe course.
[0193] However, because LOU064 does not result in depletion of the B cell pool, cessation of treatment leads to rapid restoration of full B cell function, allowing patients and treating physicians the possibility to rapidly respond to infections or vaccination requirements, particularly with live and attenuated vaccines.
[0194] According to the present invention, LOU064 may be administered during infection, such as COVID-19 infection. Thus, LOU064 administration may be continued during infection, such as COVID-19 infection.
[0195] Preferably, LOU064 administration is delayed in patients with an active infection, e.g., COVID-19, until the infection has cleared.
[0196] Thus, one embodiment of the present invention relates to LOU064 for use in the treatment or prevention of IgE-induced allergic reactions (e.g. food allergic reactions) in patients treated with acute or previously infected with COVID-19.
[0197] In a further embodiment, LOU064 treatment is continued during COVID-19 infection.
[0198] In a preferred embodiment, LOU064 treatment is interrupted during COVID-19 infection and continued after overcoming the infection.
[0199] Yet another embodiment of the invention relates to LOU064 for use in the treatment or prevention of IgE-induced allergic reactions (e.g., food allergic reactions), where the patient is vaccinated during LOU064 treatment. Alternatively, the patient may be vaccinated during LOU064 treatment with a non-live vaccine. In one embodiment, the patient is vaccinated with a quadrivalent influenza vaccine, a PPV-23 vaccine, or a KLH neoantigen vaccine during LOU064 treatment (e.g., 15 days after starting LOU064 treatment). In one aspect of this embodiment, the patient receiving the quadrivalent influenza vaccine achieves a response as defined by a >4-fold increase in anti-hemagglutinin antibody titers 28 days after vaccination compared to baseline. In another aspect of this embodiment, the patient receiving the PPV-23 vaccine achieves a >2-fold increase in IgG titers 28 days after vaccination compared to baseline. In yet another embodiment, the patient receiving the KLH neoantigen vaccine achieves a T-cell dependent antibody response as measured by anti-KLH IgG and IgM titers 28 days after vaccination.
[0200] Another embodiment of the invention relates to LOU064 for use in the treatment or prevention of an IgE-induced allergic reaction (e.g. a food allergic reaction) where LOU064 treatment is discontinued for vaccination, in particular where LOU064 treatment is discontinued 5-10 days, such as 7 or 8 days, preferably 6 weeks, before vaccination and continued after vaccination, such as 5-20 days, preferably 5-10 days, or most preferably 10-15 days after vaccination. In an alternative embodiment, the vaccination is vaccination with a live and / or attenuated vaccine. In a particular aspect of this embodiment, the patient is vaccinated with a quadrivalent influenza vaccine, a PPV-23 vaccine, or a KLH neoantigen vaccine after discontinuing LOU064 treatment (e.g. 5-10 days or 7 or 8 days after discontinuing LOU064 treatment). In one aspect of this embodiment, the patient receiving the quadrivalent influenza vaccine achieves a response as defined by a >4-fold increase in anti-hemagglutinin antibody titers at 28 days after vaccination compared to baseline. In another aspect of this embodiment, patients receiving the PPV-23 vaccine achieve a >2-fold increase in IgG titers 28 days after vaccination compared to baseline. In yet another embodiment, patients receiving the KLH neoantigen vaccine achieve a T cell dependent antibody response as measured by anti-KLH IgG and IgM titers 28 days after vaccination. LOU064 treatment is then continued beginning 29 days after vaccination.
[0201] General Provisions The details of one or more embodiments of the present disclosure are described in the accompanying description above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are described herein. Other features, objects, and advantages of the present disclosure will be apparent from the specification and claims. In this specification and the appended claims, the singular form includes plural referents (e.g., a reaction may include several reactions) unless the context clearly dictates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the disclosure belongs. All patents and publications cited herein are incorporated by reference. The following examples are presented to more particularly illustrate the preferred embodiments of the present disclosure.
[0202] These examples should in no way be construed as limiting the scope of the disclosed subject matter, which is defined by the appended claims. EXAMPLES
[0203] Example 1: Passive Cutaneous Anaphylaxis (PCA) in Mice LOU064 was tested in a mouse PCA model. BALB / c mice aged 8-10 weeks were used for the model. For passive sensitization with hapten-specific IgE, mice under isoflurane anesthesia received an intradermal injection of 20 μl of anti-DNP IgE in saline in the right ear and 20 μl of saline in the left ear. For FcεR-specific PCA, mice received a low dose of 3 ng of anti-DNP IgE. For maximum PCA, mice received a high dose of 25 ng of anti-DNP IgE.
[0204] LOU064 was administered orally (po) in a volume of 5 ml / kg body weight. The first dose was administered 4 hours after sensitization in the evening before challenge. The next morning, 2 hours before hapten challenge, mice were given a second oral dose of LOU064. Mice were challenged with hapten 2 hours after the second dose by placing them in a heated chamber. Animals were then intravenously (iv) injected with 100 μg of hapten DNP-HSA (dinitrophenyl-human serum albumin) in 200 μl of 2% Evans Blue diluted in PBS. Mice were then returned to their cages for exactly 30 minutes. After 30 minutes, animals were then anesthetized with isoflurane and bled retro-orbitally using EDTA-coated blood collection tubes for analysis of compound exposure. Mice were then sacrificed by cervical dislocation. 6 mm punch biopsies were taken from both the left and right ears and placed in 100 μl of formalin. The skin biopsies were incubated at 80° C. overnight to extract the dye. After 24 hours, 80 μl of formalin solution was transferred to a clear flat-bottom 96-well plate and light absorption was read at 620 nm. Analysis was performed by subtracting the left ear (saline) from the right ear (IgE) to determine how much dye was released into the skin tissue of the biopsies. Statistical significance was determined by ANOVA. Spleens were removed for BTK occupancy analysis.
[0205] Analysis of blood concentration: Blood samples were taken as indicated and compound measurements were performed. The blood samples were spiked with structurally similar internal standards mixed with acetonitrile (4 volumes) and centrifuged at approximately 4000 rpm (4° C.). The supernatant was then transferred to a microtiter plate. An aliquot of each sample was injected into the LC-MS / MS system for determination of the concentration of the parent molecule.
[0206] The concentrations of LOU064 present in the mouse blood 2.5 hours after the second compound administration are shown in Table 1 for low dose IgE sensitization.
[0207] [Table 1]
[0208] Analysis of BTK occupancy in the spleen (Figure 2) The level of BTK occupancy after administration of LOU064 was determined in separate ELISAs for total BTK protein and bound BTK (=free BTK). Covalent binding of compounds to BTK was determined using immunoassays for free BTK (i.e., not covalently occupied by compound) and total BTK protein. For free BTK measurements, samples were incubated with a biotinylated covalent BTK probe (Pulz R et al, ACS Med. Chem. Lett. 2019, 10, 1467-1472) and then samples were added to a streptavidin ELISA plate to allow binding of probe-bound BTK. Probe binding to BTK is mutually exclusive with compound binding to BTK. Plate-bound BTK was detected using an anti-BTK antibody (D3H5, Cell Signaling Technology). For total BTK measurements, ELISA plates were coated with D3H5 anti-BTK to capture total BTK. The captured BTK was then detected using an anti-BTK antibody (no. 53, BD Biosciences) directed against a different epitope. The respective free BTK levels for each sample were normalized to the total BTK levels in the same sample, and these ratios were expressed as a percentage of the vehicle control sample.
[0209] For splenic BTK occupancy, each spleen was ground and lysed in 0.4 ml cold Pierce IP Lysis Buffer (Thermo Scientific #87787) containing protease inhibitor cocktail (Complete, Roche #11 836 170 001) and 5 mM EDTA on ice for 10 min in a GentleMACS (Miltenyi, #130-093-236) tube. Spleen lysates were removed by centrifugation and an aliquot was incubated with 10 μM covalently bound biotinylated BTK probe for 2 h at room temperature. Two separate ELISA assays were performed to determine the relative levels of total BTK protein and BTK-bound covalent probe (representing free unoccupied BTK).
[0210] Relative BTK occupancy was calculated as the ratio of free BTK (signal of bound BTK) to total BTK for each sample: Ri = free BTK / total BTK. Individual Ri values were then normalized to the vehicle group, giving a percent occupancy: (Ri vehicle group mean - Ri) / (Ri vehicle group mean). * Expressed as 100%.
[0211] Figure 2 shows the relative BTK occupancy in the spleen 2.5 hours after the second oral dose of LOU064. High and near-maximal levels of BTK occupancy were seen for all dose levels. Occupancy levels relative to vehicle control were 89.1% ± 1.7 for the 3 mg / kg dose and 98.4-99.7% for doses from 10 to 100 mg / kg.
[0212] Conclusion: Based on the above results, the BTK inhibitor, LOU064, is effective in inhibiting FcεR responses in cutaneous mast cells (Figure 1). The study showed that near-complete inhibition of anaphylactic reactions was observed at doses as low as 3 mg / kg. Blood concentrations of LOU064 2.5 h after the second oral dose showed a dose-proportional increase. Blood exposure in both experiments was comparable. Splenic BTK occupancy measured at the same time point showed near-complete target occupancy with proportionality for the lower dose. In conclusion, LOU064 was demonstrated to significantly inhibit cutaneous anaphylaxis in the mouse PCA model after two oral doses.
[0213] Example 2: Reverse passive Arthus (RPA) reaction in mouse skin The effect of a single dose of LOU064 was tested in an acute mouse reversed passive Arthus (RPA) model to evaluate its effect on cutaneous anaphylactic reactions triggered by IgG immune complexes and mediated by FcGRIII on mast cells. 8-10 week old female C57Bl6 mice (Charles River, France) were used. The backs of the mice were shaved 24 hours before cutaneous injection. This allowed any potential irritation of the skin to be resolved. Arthus reactions were triggered 2 hours after the compound in dose-response studies or at the indicated time points in time-course studies. To trigger the Arthus reaction, 50 μl of PBS (control site) or polyclonal rabbit anti-ovalbumin IgG at a concentration of 30 μg in PBS (C6534, Sigma) was injected intradermally (id) in the dorsal skin. Immediately after the intradermal injection, an intravenous (iv) injection of 200 μl of ovalbumin (20 mg / kg) in saline (05450 Fluka) was performed. Three hours after ovalbumin injection, mice were sacrificed and bled for compound concentration monitoring, and spleens were removed for BTK occupancy measurements. The thickness of the injected control and anti-ovalbumin IgG skin sites was measured using digital calipers, and the thickness of the anti-ovalbumin IgG injected site minus the saline control site was then calculated for mice in all treatment groups.
[0214] The effect of LOU064 treatment on skin swelling in mice administered as a single oral (po) nanosuspension gavage of 3, 10, 30 and 100 mg / kg is shown in Figure 3. Compared to vehicle-treated mice, LOU064 administered 2 hours prior to the time of Arthus reaction induction demonstrated a dose-related reduction in skin swelling response at the 3 hour time point. Inhibition of the Arthus reaction was statistically significant at 73.0% ± 14.6 and 61.2% ± 14.5 at the two higher doses of 30 and 100 mg / kg, respectively.
[0215] Analysis of LOU064 levels in blood Blood samples were taken as indicated and compound measurements were performed. Structurally similar internal standards mixed with acetonitrile (4 volumes) were added to the blood samples and centrifuged at approximately 4000 rpm (4° C.). The supernatants were then transferred to a microtiter plate. An aliquot of each sample was injected into the LC-MS / MS system for determination of the concentration of the parent molecule. The concentration of LOU064 present in mouse blood 5 hours after LOU064 administration is shown in Table 2.
[0216] [Table 2]
[0217] BTK occupancy analysis: For BTK occupancy in the spleen, the experiment was performed as described in the PCA example. For lung BTK occupancy, lysates were prepared from intact lungs including trachea after the organs were perfused with saline to remove blood as for the spleen (except that the lysis buffer volume was 500 μl). Lung lysates were then analyzed for free BTK in a separate ELISA. This consisted of a capture step with anti-BTK (Cell Signaling Technologies, #8547, carrier free). The captured BTK protein was then incubated with 1 μM of covalently bound biotinylated BTK probe for 1 h at room temperature. The BTK-bound biotinylated probe was detected by streptavidin-HRP conjugate (Cell Signaling Technologies, #3999, used at a dilution of 1:1'000) and chemiluminescent substrate (Supersignal ELISA Pico, Thermo Scientific, #37070). Luminescence values were corrected for ELISA background readings from control samples measured in the absence of BTK capture antibody for the total BTK ELISA and in the absence of probe for the BTK binding ELISA, respectively. Relative BTK occupancy was calculated for each sample as the ratio of free BTK to total BTK (signal of covalently attached biotinylated probe-bound BTK): R = free BTK / total BTK. Individual Ri values were then normalized to the vehicle group, giving a percent occupancy: (Ri vehicle group mean - Ri) / (Ri vehicle group mean). * Expressed as 100%.
[0218] Figure 4 shows the relative BTK occupancy in the spleen 5 hours after oral administration of LOU064. A dose-dependent increase in BTK occupancy was observed, achieving mean BTK occupancy of 68.1% ± 10.0 at 3 mg / kg, 82.1% ± 2.92 at 10 mg / kg, 91.3% ± 3.62 at 30 mg / kg, and 99.3% ± 0.7 at 100 mg / kg.
[0219] In a subsequent study, we evaluated the duration of the pharmacological action of LOU064 in the skin. When the Arthus reaction was induced at the same time point as in the previous study, 2 hours after oral administration of 30 mg / kg LOU064, the inhibition of skin swelling was maximal at 65.7% (±14.6). At this time point, the effect was within a similar range to the previous study. When the Arthus reaction was induced at a later time point, it was found that the pharmacological action of LOU064 in the skin returned to the level of the vehicle group by the 45 hour time point (Figure 5).
[0220] From the same animals, BTK occupancy in the spleen and lungs was analyzed at the termination time point (3 hours after initiating the Arthus reaction). BTK occupancy in the spleen and lungs followed very similar kinetics compared to the pharmacological effect on skin swelling (Figure 6).
[0221] Compound exposure was assessed at the first time point following a single dose of 30 mg / kg LOU064 (Table 3).
[0222] [Table 3]
[0223] Conclusion: This experiment demonstrated the effect of LOU064 in murine RPA, a model of delayed cutaneous anaphylaxis mediated by IgG immune complexes and inflammatory FcγR. Oral treatment with a single dose of LOU064 at 3, 10, 30, and 100 mg / kg, 2 hours prior to induction of the RPA response, dose-dependently reduced skin swelling 3 hours after immune complex challenge. Skin swelling inhibition was statistically significant at both the 30 and 100 mg / kg doses. Blood concentrations of LOU064 5 hours after oral dosing increased with dose, showing some overproportionality. It is unclear whether this limited overproportionality reflects changes in Tmax or AUC. Splenic BTK occupancy measured 5 hours after dosing showed a dose-dependent increase and reached a maximum level. At the two lower doses of 3 and 10 mg / kg, splenic occupancy appeared to exceed the effect on skin swelling. This may reflect slightly slower target occupancy kinetics after a single dose of the poorly perfused skin compared to the highly perfused spleen. The pharmacological effect of LOU064 after a single dose of 30 mg / kg was maximal when the Arthus reaction was elicited 2 hours after oral administration. When the Arthus reaction was elicited at later time points, the effect decreased, reaching a level similar to the vehicle group at 45 hours after administration. The baseline drift of skin swelling inhibition toward the last time point may be due to an increased response to Arthus challenge across groups over time. The vehicle group was measured on day 1 at the same time as the 2 and 5 hour compound groups. Over the same time course, BTK occupancy was monitored in the spleen and lung. In both tissues, BTK occupancy followed very similar kinetics compared to the pharmacological effect on skin swelling. In the absence of a sufficiently sensitive method to measure BTK occupancy in the skin, it may be assumed that skin BTK occupancy after a single oral dose of LOU064 follows similar kinetics to spleen occupancy and skin pharmacology. In conclusion, LOU064 was demonstrated to significantly and dose-dependently inhibit skin swelling in the murine reverse passive Arthus model after a single oral administration.
[0224] Example 3: Ovalbumin-induced anaphylaxis mouse model This experiment was performed to examine the anti-inflammatory effects of LOU064 (10 mg and 30 mg / Kg) in OVA-sensitized mice injected with polyinosinic-polycytidylic acid (Poly I:C).
[0225] [Table 4]
[0226] animal: Male Balb / c mice (20-30 g, Charles Rivers UK Ltd) were housed in five cages for 7 days prior to the start of the study and were subjected to a 12:12 h light:dark cycle. Mice were fed standard mouse chow and had water available ad libitum.
[0227] Allergen Exposure: Mice were actively sensitized with ovalbumin (15 μg, subcutaneously (sc)) and 25 μL of Imject Alum on days 0, 7, and 14. To induce a local inflammatory response in the lungs, mice were repeatedly exposed to an aerosol of 1% w / v ovalbumin in phosphate-buffered saline (PBS) generated by an ultrasonic nebulizer (Aerogen) for 20 min on days 21-24. Sixteen hours after the last exposure to OVA on day 24, polyinosinic-polycytidylic acid (Poly I:C, 100 μg / animal) or vehicle (PBS) was delivered intratracheally using a Microsprayer (Model IA-1C) with an FMJ-250 high-pressure syringe, Penn-Century, under anesthesia with ketamine (100 mg / Kg, intraperitoneally (ip)) and xylazine (10 mg / Kg, intraperitoneally (ip)).
[0228] LOU064 and vehicle treatment: Mice were dosed orally (po) with LOU064 or vehicle (0.5% Tween 80 / 0.5% methylcellulose (400cP) / 99% water) twice daily (BID) followed by a single dose of vehicle (67% PEG200 / 33% PBS) 1 hour prior to Poly I:C.
[0229] [Table 5]
[0230] Bronchoalveolar lavage (BAL) and cell counts: 24 hours after the last OVA challenge, blood samples were collected by venipuncture into pre-chilled Li Hep tubes. Each sample was gently mixed and kept on wet ice for a maximum of 15 minutes before being centrifuged (1500g, 10 minutes at 4°C) to prepare plasma. Each sample was aliquoted and stored at -80°C until transport. Immediately after blood collection, animals were sacrificed by overdose of pentobarbital. The trachea was then isolated by midline incision in the neck and separation of the muscle layer. A small incision was made in the trachea and a plastic cannula was inserted and fixed in place with sutures. The airway was then lavaged by flushing the lungs with 0.5 mL of phosphate buffered saline. This procedure was repeated until the recovered volume was 1.6 mL. The isolated BALF was then centrifuged at 1500 rpm for 10 minutes at 4°C and the supernatant was aliquoted (400 μL) at -80°C for any future cytokine analysis. The cell pellet was then resuspended in 1.6 mL of phosphate buffered saline and BAL cells were analysed for total and differential numbers. Total and differential cell counts of BAL fluid samples were measured using an XT-2000iV analyser (Sysmex). Differentially classified cell types were eosinophils (Figure 8), neutrophils (Figure 9), or mononuclear cells (macrophages (Figure 10) and lymphocytes (Figure 11).
[0231] Conclusion: Treatment with LOU064 (10mg / kg, 30mg / Kg) significantly reduced the numbers of cells involved in pulmonary anaphylaxis (eosinophils, basophils, macrophages and lymphocytes).
[0232] Example 4: Inhibition of FcεR-induced mast cell degranulation in LAD2 cells Rationale and Methods: The human mastocytosis cell line LAD2 expresses FcεRI and upon receptor cross-linking, the cells degranulate and release inflammatory mediators such as β-tryptase and hexosaminidase (Wernersson et al. 2014, Immunology;14(7):478-94). The assay involves 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) haptenized bovine serum albumin (BSA) and the NIP-specific chimeric IgE antibody JW8 (Neuberger, MS et al. (1985), Nature 314(6008), pp 268-70. doi:10.1038 / 314268a0). LAD2 cells were sensitized with JW8 IgE antibody and then incubated with serial compound dilutions for 30 min at 37°C. Degranulation was then triggered by adding haptenylated NIP-BSA to crosslink FcεR. After 1 h, supernatants were collected and analyzed for β-tryptase levels.
[0233] Results: Consistent with its potent activity in the basophil activation assay, LOU064 demonstrated potent inhibition of IgE / FcεR-induced mast cell degranulation in LAD2 cells with an IC50 of 7.0 nM ± 2.6 (n = 3).
[0234] Example 5: Inhibition of FcεR-induced degranulation of peripheral blood mononuclear cell (PBMC)-derived mast cells Rationale and Methods: Primary human mast cells were obtained from CD34-positive progenitor cells isolated from PBMCs (Neuberger, MS et al. (1985), Nature 314(6008), pp 268-70. doi:10.1038 / 314268a0). Blood from healthy volunteers was donated under informed consent and transferred to the Novartis Tissue Donor Centre in accordance with the Swiss Human Research Act and approval by the responsible ethical committee (Ethikkommission Nordwest-und Zentralschweiz). Mast cells were collected by the ELISA program. Briefly, CD34 positive cells were isolated from peripheral blood by positive selection and cultured in medium containing SCF, IL-6 and IL-3. After 6 weeks of differentiation culture, mast cells were collected and phenotypically characterized for the expression of c-Kit (CD117) and FcεRI. Degranulation was based on NIP-haptenized BSA and NIP-specific chimeric IgE antibody JW8 (described in RD-2013-00412). Mast cells were sensitized with JW8 IgE antibody and then incubated with serial compound dilutions for 30 min at 37°C. Degranulation was then triggered by adding haptenized NIP-BSA to crosslink FcεR. After 1 h, supernatants were collected and analyzed for β-tryptase levels.
[0235] Results: Similar to other FcεR inhibitory activities, LOU064 potently and completely blocked in vitro degranulation of primary human PBMC-derived mast cells with an IC50 of 5.7 nM ± 2.4 (n = 7 donors).
[0236] Example 6: Inhibition of skin-derived human mast cells. Rationale and Methods: Skin tissue was used as a source of primary human tissue mast cells. Surgical skin waste samples were provided under informed consent and collected by the University Hospital Basel in accordance with the Swiss Human Research Act and approval by the responsible ethical committee (Ethikkommission Nordwest und Zentralschweiz). Skin tissue was dissociated and intact mast cells were prepared according to the protocol of Kulka and Metcalfe (Kulka et al. 2010, current protocol in Immunology; SUPPL. 90:1-11). Isolated mast cells were phenotypically characterized and used in degranulation assays as described above ((Neuberger, MS et al. (1985), Nature 314 (6008), pp 268-70. doi:10.1038 / 314268a0). Mast cells were sensitized with JW8 IgE antibody and then preincubated with serial compound dilutions for 30 min at 37°C. Degranulation was then triggered by adding haptenylated NIP-BSA to crosslink FcεRI. After 30 min, supernatants were collected and analyzed for histamine using an HTRF-based immunoassay (Cisbio Bioassays).
[0237] Results: Similar to its activity in previous types of FcεRI-induced cell signaling, LOU064 potently inhibited histamine release from human primary skin-derived mast cells with an IC50 of 16.5 nM ± 5.0 (n = 2 donors).
[0238] The in vitro intracellular potency of LOU064, assessed across several cell types in Examples 4-6, supports its use in allergic diseases driven by the FcεR pathway.
[0239] Example 7: Dosage of LOU064 (Rationale) In a mouse PCA model, LOU064 was demonstrated to be effective in inhibiting FcεR responses in cutaneous mast cells at doses as low as 3 mg / kg (Figure 1). Splenic BTK occupancy, which may be a more relevant biomarker for predicting efficacy in the prevention and / or treatment of IgE-induced allergic reactions (especially food allergic reactions), shows near-complete occupancy at 10 and 100 mg / kg.
[0240] It was further demonstrated that in mice, BTK occupancy in the spleen and lung followed very similar kinetics (Figure 6).
[0241] It was also demonstrated that LOU064 was effective in reducing skin swelling in a mouse RCA model, primarily at high doses (73% inhibition of the Arthus reaction at 30 mg / Kg).
[0242] Importantly, it was also demonstrated that LOU064 treatment of mice in an ovalbumin-induced anaphylaxis model resulted in a significant reduction in the number of cells involved in pulmonary anaphylaxis at doses of 10 mg / kg and 30 mg / kg.
[0243] All preclinical results support an effective dose for LOU064 in mice of around 10 mg / kg. 30 mg / kg has also been shown to be effective in mice.
[0244] Additional BTK occupancy in human spleen was predicted using a translational PK / PD model to further aid dose selection.
[0245] Prediction of BTK occupancy using a translational PK / PD model for LOU064 BTK occupancy in blood is not a useful biomarker for dose selection due to LOU064 pharmacological properties (irreversible binding). It reaches full occupancy even at low doses before showing pharmacological activity by other biomarkers (CD63, CD203c, skin prick test). Occupancy in tissues may be more representative of the predicted efficacy of LOU064.
[0246] the purpose The objectives of this analysis were to characterize the pharmacokinetics (PK) of LOU064 in healthy volunteers and to simulate BTK occupancy in human spleen / tissues across a range of doses and dosing regimens (twice daily (BID) vs. once daily (QD)) using a previously developed, translational target occupancy model.
[0247] data Pharmacokinetic data from a phase I clinical trial reported by Kaul et al. (2021), including 102 patients, were used in the present analysis.
[0248] method A translational target occupancy model to simulate BTK occupancy in spleen / tissues was developed using a two-step approach.
[0249] In the first step, a population PK model was established to explain the LOU064 PK data from the Phase I clinical trial reported by Kaul et al. (2021). In the second step, parameter estimates from the population PK model were used in a BTK occupancy model to predict BTK occupancy in blood and spleen / tissues. Finally, the BTK occupancy model was used to predict BTK occupancy in spleen / tissues for different dosing regimens (once daily (QD), twice daily (BID)) at different doses.
[0250] result A population PK model was developed to explain the intermediate PK from the Phase I clinical trial reported by Kaul et al. (2021). To address the change in clearance after repeated dosing of doses less than 50 mg (lower clearance at steady state on day 12 compared to day 1 with no difference at higher doses), clearance was modeled as a function of exponential time decay for doses less than 50 mg and constant clearance for doses greater than 50 mg. Overall, the resulting population model explained the PK data to some extent.
[0251] The PK parameter estimates were used in a translational BTK occupancy model to simulate BTK occupancy at steady state. The BTK occupancy simulations showed that twice-daily (BID) dosing was more effective than once-daily (QD) dosing of the same dose for achieving higher BTK occupancy (at the trough or averaged over a 24-hour interval).
[0252] Trough and average steady-state BTK occupancy over a 24-hour period for selected dosing frequencies for once-daily (QD) and twice-daily (BID) regimens are shown in Figure 14A (Trough BTK occupancy over 24 hours) and Figure 14B (Average BTK occupancy over 24 hours) for dosing regimens of 10 mg, 35 mg, 100 mg once-daily and 10 mg, 25 mg, and 100 mg twice-daily, respectively. Both figures show that a daily dose of up to 200 mg (100 mg twice-daily (BID)) may be required to achieve trough BTK occupancy > 80% in peripheral target tissues.
[0253] Simulations were performed to compare different dosing regimens. A comparison of simulated splenic BTK occupancy at steady state for 100 mg twice daily (BID) versus 100 mg once daily (QD) over time is shown in Figure 13. The graph shows that occupancy from twice daily (BID) dosing is higher and less variable compared to QD dosing, as would be expected from first principles.
[0254] Conclusion: BTK occupancy simulations showed that twice-daily (BID) dosing was more effective than once-daily (QD) dosing of the same dose for achieving higher BTK occupancy (at trough or averaged over a 24-hour period).
[0255] Based on the conversion model between animals and humans (Journal of basic and clinical pharmacy,7(2),27-31), the calculated human equivalent dose (HED) for 30mg / kg corresponds to approximately 170mg for a 70kg person, and the calculated human equivalent dose (HED) for the minimally effective dose of 10mg / kg corresponds to approximately 56mg for a 70kg person (Nair,AB,& Jacob,S.(2016).
[0256] Finally, predictive models of splenic BTK occupancy in humans showed that twice-daily (bid) dosing was more effective than once-daily (QD) dosing of the same dose for achieving higher BTK occupancy (Figure 13). Thus, a dose of 25 mg bid of LOU064 is shown to be the minimum human effective dose, with a dose of 100 mg bid also being effective in humans.
[0257] Example 8: Clinical Trial Peanut Allergy Phase 2 A randomized, double-blind, placebo-controlled, 4-week study evaluating three dosing regimens (LOU064 10 mg twice daily (BID), 25 mg twice daily (BID), and 100 mg twice daily (BID)) in adult patients with indicated peanut allergy.
[0258] The "Peanut Study" is evaluating the efficacy of LOU064 (10 mg twice daily (BID), 25 mg twice daily (BID), and 100 mg twice daily (BID)) compared to placebo in the proportion of patients free of objective allergic reactions to a double-blind, placebo-controlled, oral food challenge (DBPCFC) of 600 mg peanut protein after 4 weeks of treatment. In addition, patients treated with LOU064 25 mg twice daily (BID) for only 1 week will be similarly compared to placebo, evaluating the proportion of patients free of objective allergic reactions to DBPCFC of 600 mg peanut protein. Secondary endpoints for all treatment arms include response to 1000 mg and 3000 mg peanut protein.
[0259] Example 9: Clinical Trial Peanut Allergy Phase 3 A randomized, double-blind, placebo-controlled, 10-18 week study evaluating LOU064 in approximately 300 adults and adolescents (ages 12-55) with demonstrated peanut allergy. The peanut study will evaluate the efficacy of LOU064 compared to placebo in the proportion of participants without objective allergic reactions to a double-blind, placebo-controlled, oral food challenge (DBPCFC) of 600 mg, 1000 mg, and 3000 mg peanut protein levels at 1 or 2 weeks.
[0260] Example 10: Clinical Trial Milk and Egg Allergy A randomized, double-blind, placebo-controlled, 10- to 18-week basket study evaluating LOU064 in approximately 450 adult and adolescent participants aged 12-55 years with an indicated nut, milk, or shrimp allergy.
[0261] The basket study evaluating nut, milk and shrimp allergens is evaluating the efficacy of LOU064 compared with placebo in the proportion of patients free of objective allergic reactions to multiple levels of DBPCFC of 1'000 mg (non-cumulative) and 3'000 mg (non-cumulative) nut / milk / shrimp protein at 1 or 2 weeks.
[0262] Example 11: 100 mg film-coated tablet A preferred pharmaceutical composition (film-coated tablet) is shown below.
[0263] [Table 6]
[0264] Example 12: 25 mg film-coated tablet A preferred pharmaceutical composition (film-coated tablet) is shown below.
[0265] [Table 7]
[0266] Example 13: 10 mg film-coated tablet A preferred pharmaceutical composition (film-coated tablet) is shown below.
[0267] [Table 8]
[0268] Example 14: Safety of LOU064 The safety of LOU064 has been studied in Phase I and II pharmacokinetic and clinical pharmacology healthy subject studies and Phase II / III clinical trials conducted in patients with indications other than MS, specifically chronic spontaneous urticaria (CSU) and Sjögren's syndrome (SjS).
[0269] Short-term safety of LOU064 in Phase I clinical trials The short-term safety of LOU064, administered as a single dose or as multiple doses covering a dose range of 0.5 mg to 600 mg for up to 18 days, and also at 100 and 200 mg twice daily (bid) for up to 12 days, has been demonstrated in phase I clinical trials (Kaul, M. et al. (2021). Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and Translational Science. 10.1111 / cts.13005).
[0270] Summary of safety in the Phase 2b extension phase of CSU subjects (interim results) In a 52-week open-label extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who participated in a Phase 2b study, the dose used was 100 mg twice daily (bid).
[0271] No safety signals were observed based on an interim analysis of 100 subjects who received at least one dose of LOU064 with a median exposure of 17.86 weeks (range: 2.9 weeks to 44.7). At the time of cutoff, 93 subjects (93%) were continuing and 7 subjects had discontinued the study; none of the discontinuations were due to adverse events. Table 4 shows a summary of safety observed in the Phase 2b study through the cutoff date for the interim analysis.
[0272] [Table 9]
[0273] Fifty-eight subjects (58%) experienced at least one treatment-emergent AE. The majority of AEs were non-serious, did not lead to treatment discontinuation, and were mild in severity. The most frequently affected SOC was infections and infestations (14%), followed by skin and subcutaneous tissue disorders (13%), with no trends for specific adverse events. The most common adverse event preferred terms (≥2%) were headache (6%), diarrhea (4%), dizziness (3%), and gastroenteritis (3%); no bleeding events (defined as events under the SMQ Bleeding broad and PTs including platelet aggregation abnormalities, platelet aggregation decreased, platelet aggregation inhibition, platelet function disorders, platelet function test abnormalities, and platelet toxicity) or events under SOC Blood and lymphatic system disorders were reported. Three SAEs were reported: ovarian cyst, chest pain, and appendicitis; none were considered related to study drug.
[0274] Conclusions from the Phase 2b study and corresponding open-label extension study Combined, there were no safety findings in the Phase 2b studies across all doses evaluated. Additionally, in the corresponding CSU extension study using open-label LOU064 100 mg twice daily (bid), no safety signals were observed in the 100 subjects enrolled as of 31-Aug-2020. The highest dose offered, 100 mg LOU064 twice daily (bid), was deemed well tolerated and had a favorable safety profile.
[0275] Summary of safety in Phase 2b study (extension phase) in CSU subjects (interim results / patients with median exposure of 35.14 weeks) In the above 52-week open-label extension study to evaluate the long-term safety and tolerability of LOU064 at a dose of 100 mg twice daily (bid) in eligible subjects with CSU enrolled in a Phase 2b study, a new interim analysis was conducted in patients (N=183) with a median exposure of 35.14 weeks and results were compared to safety results in a randomized, double-blind, placebo-controlled Ph2b core study in adult patients with CSU receiving (1:1:1:1:1:1:1) remibrutinib 10 mg qd (once daily), 35 mg qd, 100 mg qd, 10 mg bid (bid), 25 mg bid, or 100 mg bid or placebo for up to 12 weeks (wks) (NCT03926611) (Table 5).
[0276] In the longer exposure in ES (median 35.14 weeks, N=183), the proportion of patients with at least one adverse effect (AE) to remibrutinib treatment (57.4% [n=105]) was similar to CS (indicated by any remibrutinib dose) (58.1% [n=155]; median 12.14 weeks, N=267). In ES, there were four serious adverse effects (SAEs), six AEs leading to treatment discontinuation, and death. The incidence of AEs by system organ class (SOC) reported in ES and CS was similar: infections and infestations (23.0% and 24.0%), followed by skin / subcutaneous tissue disorders (17.5% and 16.9%) (Table 5). The incidence of AEs reported by preferred term was comparable in ES and CS, with headache (6.6% and 9.7%) being the most frequent. The occurrence of AESI in ES was consistent with CS, including infections (23%), hemorrhages (4.4%), and cytopenias (0.5%). There was one new-onset significant aminotransferase increase in both ES (isolated ALT >3×ULN in one patient, normalized within 4 weeks, who discontinued early for personal reasons) and CS (ALT >5×ULN in one patient, normalized to treatment). Analysis of laboratory parameters did not indicate any significant safety concerns, and no clinically significant changes in vital signs were observed. There were no significant ECG findings or QT >500 ms noted in any patient.
[0277] conclusion Remibrutinib demonstrated a favorable safety profile across the entire dose range, with no new safety signals observed over longer periods of exposure to doses of 100 mg bid for up to 52 weeks in patients with CSU.
[0278] [Table 10]
[0279] Example 15: Evaluation of the modulation of immune responses to three different types of vaccines by simultaneous and intermittent administration of remibrutinib in healthy subjects
[0280] [Table 11]
[0281] Study design Overall Design This randomized, double-blind, placebo-controlled study has a parallel-group comparative design. Approximately 90 healthy, non-childbearing potential female and male participants will be randomized into one of three treatment groups to achieve a minimum of 72 evaluable completers, allowing for an estimated dropout rate of up to 20%. The study will consist of a 28-day screening period, a 43-day treatment period, followed by a study completion assessment (Day 57) within 2 weeks after the last study drug administration. A safety follow-up call will be conducted approximately 30 days after the last study drug administration (Day 73). Participants will be settled from Days -1 to 1 and 14 to 17. Overall, the maximum study duration for each participant will be approximately 85 days.
[0282] The impact of concurrent and intermittent remibrutinib treatment scenarios / Pneumovax® 23 and Immucothel® versus placebo for influenza will be evaluated.
[0283] Testing Screening and Baseline Participants who meet the eligibility criteria at screening will undergo baseline assessments on Day -1. All baseline safety assessments must be available prior to the first dose. At baseline, participants will be randomized to one of three treatment arms, described below.
[0284] treatment All participants will receive study medication (remibrutinib 100 mg or placebo twice daily (bid)) from days 1 through 42 and will return to the clinic for an end of treatment visit on day 43. All participants will also receive the quadrivalent influenza vaccine, PPV-23 vaccine, and KLH neoantigen vaccine on day 15. Vaccinations should occur 3 hours after study medication administration.
[0285] During clinical visits and settlement (Days -1 to 1 and Days 14-17), participants will receive study medication by study personnel at the clinic. Upon discharge from clinical visits during the treatment period, participants will be given study medication to self-administer at home, along with a medication diary.
[0286] Safety assessments included physical examination, ECG, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, urinalysis), adverse events and serious adverse event monitoring.
[0287] Multiple blood samples to assess remibrutinib pharmacokinetics were obtained from all participants on days 8, 15, and 36.
[0288] Group A (concurrent remibrutinib treatment): Participants will receive placebo (twice daily (bid)) on days 1-7, followed by treatment with remibrutinib (100 mg twice daily (bid)) on study days 8-15 to achieve PK / PD steady state prior to administration of the three vaccines on day 15. Participants will continue to receive remibrutinib (100 mg twice daily (bid)) until day 42.
[0289] Group B (intermittent remibrutinib treatment): Participants will be treated with remibrutinib 100 mg twice daily (bid) on days 1-7 to achieve PK / PD steady-state conditions, followed by placebo (bid) on days 8-28 and three vaccines on day 15. Treatment with remibrutinib 100 mg twice daily (bid) will be resumed on days 29-42.
[0290] Group C (placebo): Participants in group C will receive a placebo (bid) on days 1 to 42 and then receive three vaccines on day 15 under placebo conditions.
[0291] Key eligibility criteria Signed informed consent must be obtained prior to participation in the study. Healthy or mildly obese or otherwise healthy male and female participants of non-childbearing potential, aged 18–55 years (inclusive). Participants should be in good health as determined by medical history, physical examination at screening and baseline visits, vital signs, ECG, and laboratory tests as indicated. At screening and baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position and again in the standing position (if required by the assessment schedule). Sitting vital signs (after sitting for 3 minutes) should be within the following ranges: Tympanic temperature of 35.0~37.5℃. · Systolic blood pressure (SBP) between 90 and 139 mmHg (endpoints included). · Diastolic blood pressure (DBP) between 50 and 89 mmHg (end points included). · Pulse rate between 45 and 90 bpm (end points included). Participants must weigh at least 50kg to take part in the study and have a body mass index (BMI) within the range of 18-34.9kg / m2. Participants must be willing to remain at the clinical site when required by the protocol and to follow the requirements / instructions outlined in the ICF. ·Ability to read, speak and understand the local language in order to understand and comply with the examination requirements.
[0292] Key Exclusion Criteria Use of other investigational drugs within 1.5 half-lives or 30 days prior to the first dose, whichever is longer.
[0293] 2. Current evidence or personal history of clinically significant ECG abnormalities or family history (grandparents, parents, and siblings) of Long QT Syndrome or other abnormalities in cardiac conduction, history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia) and / or known medical history or current clinically significant arrhythmias. Abnormal ECG defined as PR>220msec, QRS complex>120msec, QTcF>450msec for males and females, or any other morphologic changes other than early repolarization, nonspecific ST or T wave changes.
[0294] 3. History or presence of treated or untreated malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical carcinoma) within the past 5 years, with or without evidence of local recurrence or metastasis.
[0295] 4. History or presence of any clinically significant disease of any organ system class, including (but not limited to) cardiovascular, pulmonary, metabolic, hepatic, renal, hematological, endocrine, neurological or psychiatric disorders, that has not resolved within 2 weeks prior to the first dose.
[0296] 5. Hypersensitivity to remibrutinib or to drugs from the same compound class or its excipients.
[0297] 6. Any contraindication to the use of Pneumovax 23, influenza or KLH vaccines, including any acute infection, fever, or hypersensitivity reaction or known hypersensitivity to any relevant components of the vaccines administered in this study (e.g., chicken egg or shellfish / KLH).
[0298] 7. History of vaccination with the 2022-2023 seasonal influenza vaccine or known clinical diagnosis of influenza infection during the 2022-2023 influenza season prior to enrollment.
[0299] 8. History of previous exposure or immunization with KLH. The present invention may include the following aspects. [1] A BTK inhibitor, e.g., an irreversible BTK inhibitor, e.g., LOU064 or a pharma- ceutically acceptable salt thereof, for use in treating or preventing an IgE-induced allergic reaction to one or more allergens, e.g., a food, drug, or toxin allergic reaction, e.g., treating or preventing an anaphylactic reaction. [2] LOU064 or a pharma- ceutically acceptable salt thereof for use according to [1] above, wherein the one or more allergens include or are a food allergen. [3] LOU064 or a pharma- ceutically acceptable salt thereof for use according to [2] above, wherein the food allergen is selected from peanuts, nuts, milk, wheat, eggs, soybeans, sesame, seafood, in particular peanuts. [4] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1], [2] or [3] above, wherein LOU064 is administered at a dose of about 20 mg to about 200 mg daily. [5] LOU064 or a pharma- ceutically acceptable salt thereof for the use according to the above [4], wherein LOU064 is administered at a dose of about 10 mg twice a day to about 100 mg twice a day. [6] LOU064 or a pharma- ceutically acceptable salt thereof for use according to [5] above, wherein LOU064 is administered at a dose of about 10 mg twice a day. [7] LOU064 or a pharma- ceutically acceptable salt thereof for use according to [5] above, wherein LOU064 is administered at a dose of about 25 mg twice a day. [8] LOU064 or a pharma- ceutically acceptable salt thereof for use according to [5] above, wherein LOU064 is administered at a dose of about 100 mg twice a day. [9] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1] to [8] above, wherein LOU064 is administered for a short period of time, for example less than 6 months, preferably less than 3 months or less than 1 month.
[10] LOU064 or a pharma- ceutically acceptable salt thereof for the use according to [9] above, wherein LOU064 is administered for a period of up to 18 weeks, for example for a period of 4, 10, 12, 16 or 18 weeks.
[11] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1] to [8] above, wherein LOU064 is administered for a long period of time, for example for more than 6 months, preferably for one year or more.
[12] LOU064 or a pharma- ceutically acceptable salt thereof for the use according to
[10] or
[11] above, wherein LOU064 is administered as monotherapy.
[13] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1] to
[12] above, wherein LOU064 is not administered simultaneously with a potent inhibitor of CYP3A, for example a potent inhibitor of CYP3A4.
[14] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1] to
[11] or
[13] above, wherein LOU064 is co-administered with a therapeutic agent.
[15] LOU064 or a pharma- ceutically acceptable salt thereof for use according to
[14] above, wherein LOU064 is co-administered with a corticosteroid and / or an immunosuppressant (e.g., an inhaled corticosteroid), a leukotriene receptor antagonist (LTRA), a short-acting beta agonist (SABA) or a long-acting beta agonist (LABA).
[16] A BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for use according to any one of [1] to
[11] or
[13] above, wherein LOU064 is co-administered with oral immunotherapy (OIT), sublingual immunotherapy (SLIT), transdermal immunotherapy (EPIT), preferably OIT.
[17] A BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for use according to
[16] above, wherein LOU064 is an adjuvant for oral immunotherapy (OIT), sublingual immunotherapy (SLIT), or transdermal immunotherapy (EPIT), preferably OIT.
[18] The BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for use according to
[16] or
[17] above, wherein the oral immunotherapy is a peanut protein (e.g., Palforzia™).
[19] A BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for use according to any one of
[16] to
[18] above, wherein LOU064 is administered starting at least 2 days (e.g., at least 2 to 14 days) prior to administration of the oral immunotherapy.
[20] The BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for use according to
[19] above, wherein the BTK inhibitor, such as LOU064, is administered during the titration phase of the immunotherapy treatment.
[21] A BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for use according to any one of the above [1] to
[20] , wherein the method is prevention of an IgE-induced allergic reaction.
[22] A BTK inhibitor, such as LOU064 or a pharma- ceutically acceptable salt thereof, for use according to any one of [1] to
[21] above for preventing anaphylaxis following accidental exposure to any allergen (e.g., a food allergen).
[23] LOU064 or a pharma- ceutically acceptable salt thereof for use according to
[21] or
[22] above, wherein LOU064 achieves maximum prevention at least 2 days (e.g., 2 to 14 days, preferably 2 to 7 days) after treatment.
[24] The patient meets the following criteria: (e) Male and female patients, aged 6 years and older (e.g., 6–11 years, 12–17 years, or 18–55 years); (f) a confirmed history of allergies to foods, including but not limited to peanuts, nuts, wheat, eggs, milk, soybeans, and seafood; (g) positive allergen-specific IgE (e.g., peanut sIgE ≥ 6 kUA / L at screening); and (h) A positive skin prick test result to an allergen to which the patient is allergic (e.g., defined as a mean diameter (longest diameter and midpoint perpendicular diameter) of ≥ 4 mm compared to a negative control). LOU064 or a pharma- ceutically acceptable salt thereof, for use according to any one of the above [1] to
[23] , selected according to one or more of the following:
[25] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1] to
[24] above, wherein the patient is an adult patient (18 years of age or older) or an adolescent (12 to 17 years of age).
[26] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1] to
[24] above, wherein the patient is a child aged 2 to 11 years, for example aged 2 to 5 years or 6 to 11 years.
[27] At least one of the following applies: After up to 4 weeks (e.g., after 1 week, or after 2 weeks, or after 3 weeks, or after 4 weeks) of treatment with LOU064, d. At least 90% of treated patients do not exhibit an allergic reaction upon a food challenge of 600 mg of peanut protein; e. At least 90% of treated patients do not exhibit an allergic reaction upon a food challenge of 1000 mg of peanut protein; f. LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of the above [1] to
[26] , wherein at least 80% of treated patients do not show an allergic reaction upon a food challenge of 3000 mg of peanut protein.
[28] LOU064 or a pharma- ceutical acceptable salt thereof for use according to any one of [1] to
[27] above, wherein the patient achieves a reduction from baseline in the total domain score FAQLQ of 0.45 to 0.5.
[29] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of [1] to
[28] above, wherein the patient achieves a reduction from baseline in the total domain score FAIM.
[30] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any of the above [1] to
[29] , wherein the observed difference in response rate between treated and untreated patients in a double-blind, placebo-controlled food challenge of 600 mg of allergen (e.g., peanut allergen) is greater than 35%, wherein the response rate is defined as less than or equal to a mild response to a 600 mg oral food challenge.
[31] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of the above [1] to
[30] , wherein by the 12th or 24th week of treatment, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipase do not change by more than 10% compared to baseline levels at the start of treatment.
[32] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of the above [1] to
[31] , wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising nano-sized particles of LOU064.
[33] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of the above [1] to
[32] , wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising nano-sized particles of LOU064 having an average particle size of from about 50 nm to about 750 nm as measured by PCS.
[34] LOU064 or a pharma- ceutically acceptable salt thereof for use according to any one of the above [1] to
[33] , wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064 and a binder in a weight ratio of about 2:1.
[35] LOU064 for use according to any of the above-mentioned [1] to
[34] , wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064, a binder and a surfactant in a weight ratio of about 2:1:0.08.
[36] LOU064 for use according to any of the above-mentioned [1] to
[33] , wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064 and a binder in a weight ratio of about 1:1.
[37] LOU064 for use according to any of the above-mentioned [1] to
[34] or
[36] , wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064, a binder and a surfactant in a weight ratio of about 1:1:0.05.
[38] LOU064 for use according to any of the above-mentioned [1] to
[37] , wherein LOU064 is administered in the form of a suitable oral pharmaceutical formulation comprising LOU064, polyvinylpyrrolidone-vinyl acetate copolymer as a binder and sodium lauryl sulfate as a surfactant.
[39] When LOU064 is measured at a temperature of about 25 °C and an X-ray wavelength, λ, of 1.5405 Å, the observed values are 7.8±0.2°2θ, 9.2±0.2°2θ, 12.0±0.2°2θ, 13.6±0.2°2θ, 15.6±0.2°2θ, 16.0±0.2°2θ, 17.8±0.2°2θ, 18.3±0.2°2θ, 18.7±0.2°2θ, 19.2±0.2°2θ, 19.9±0.2°2θ, 22.1±0.2°2θ, and 23.4±0. 2°2θ, 23.9±0.2°2θ, 24.8±0.2°2θ, 25.2±0.2°2θ, 25.5±0.2°2θ, 27.2±0.2°2θ, and 29.6±0.2°2θ.
[40] LOU064, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment or prevention of an IgE-induced allergic reaction, preferably wherein LOU064 is administered at a dose of about 10 mg twice daily to about 100 mg twice daily.
[41] Use of LOU064 or a pharma- ceutically acceptable salt thereof for the treatment or prevention of IgE-induced allergic reactions, preferably wherein said LOU064 is administered at a dose of about 10 mg twice daily to about 100 mg twice daily. To be used.
Claims
1. 2. A method for the treatment or prevention of an IgE-induced allergic reaction to one or more allergens comprising administering to said patient a therapeutically effective amount of LOU064 or a pharma- ceutical or pharmaceutical acceptable salt thereof, A pharmaceutical composition, wherein LOU064, or a pharma- ceutically acceptable salt thereof, is administered to a patient for more than six months.
2. 2. The pharmaceutical composition of claim 1, wherein the one or more allergens comprises or is a food allergen.
3. 3. The pharmaceutical composition of claim 2, wherein the food allergen is selected from peanuts, nuts, milk, wheat, eggs, soybeans, sesame, and seafood.
4. 2. The pharmaceutical composition of claim 1, wherein LOU064 is administered at a dose of about 20 mg to about 200 mg daily.
5. 5. The pharmaceutical composition of claim 4, wherein LOU064 is administered at a dose of about 10 mg twice daily to about 100 mg twice daily.
6. 6. The pharmaceutical composition of claim 5, wherein LOU064 is administered at a dose of about 10 mg twice daily.
7. 6. The pharmaceutical composition of claim 5, wherein LOU064 is administered at a dose of about 25 mg twice daily.
8. 6. The pharmaceutical composition of claim 5, wherein LOU064 is administered at a dose of about 100 mg twice daily.
9. 2. The pharmaceutical composition of claim 1, wherein LOU064 is administered for one year or more.
10. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is administered as a monotherapy.
11. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is not administered concomitantly with a CYP3A inhibitor selected from boceprevir, clarithromycin, cobicistat, conivaptan, danoprevir / ritonavir, darunavir / ritonavir, elvitegravir / ritonavir, idelalisib, indinavir, indinavir / ritonavir, itraconazole, ketoconazole, LCL161, lopinavir / ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, saquinavir / ritonavir, telaprevir, telithromycin, tipranavir / ritonavir, troleandomycin, Viekira pack, and voriconazole.
12. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is co-administered with a therapeutic agent.
13. 13. The pharmaceutical composition of claim 12, wherein LOU064 is co-administered with a corticosteroid and / or an immunosuppressant, a leukotriene receptor antagonist (LTRA), a short-acting beta agonist (SABA) or a long-acting beta agonist (LABA).
14. The pharmaceutical composition according to any one of claims 1 to 9, wherein LOU064 is an adjuvant for oral immunotherapy (OIT), sublingual immunotherapy (SLIT), transdermal immunotherapy (EPIT).
15. 15. The pharmaceutical composition of claim 14, wherein the oral immunotherapy comprises ingesting peanut protein.
16. 15. The pharmaceutical composition of claim 14, wherein LOU064 is administered beginning at least 2 days prior to administration of the oral immunotherapy.
17. 15. The pharmaceutical composition of claim 14, wherein LOU064 is administered during the titration phase of oral immunotherapy.
18. A pharmaceutical composition according to any one of claims 1 to 9 for use in preventing IgE-induced allergic reactions.
19. A pharmaceutical composition for use according to any one of claims 1 to 9 for preventing anaphylaxis after accidental exposure to any allergen.
20. 19. The pharmaceutical composition of claim 18, wherein LOU064 achieves maximal prevention after a minimum of 2 days of treatment.
21. The patient meets the following criteria: (e) Male and female patients, aged 6 years and older; (f) a confirmed history of allergies to food; (g) positive allergen-specific IgE; and (h) A positive skin prick test to an allergen to which the patient is allergic. The pharmaceutical composition according to any one of claims 1 to 9, selected according to one or more of the following:
22. The pharmaceutical composition according to any one of claims 1 to 9, wherein the patient is an adult patient (18 years or older) or an adolescent (12-17 years old).
23. The pharmaceutical composition according to any one of claims 1 to 9, wherein the patient is a child between 2 and 11 years of age.
24. At least one of the following is true: After up to 4 weeks of treatment with LOU064, d. At least 90% of treated patients do not exhibit an allergic reaction upon a food challenge of 600 mg of peanut protein; e. At least 90% of treated patients do not exhibit an allergic reaction upon a food challenge of 1000 mg of peanut protein; f) The pharmaceutical composition of any one of claims 1 to 9, wherein at least 80% of treated patients do not exhibit an allergic reaction upon a food challenge of 3000 mg of peanut protein.
25. 10. The pharmaceutical composition of any one of claims 1-9, wherein the patient achieves a reduction from baseline in FAQLQ total domain score of 0.45 to 0.
5.
26. The pharmaceutical composition of any one of claims 1 to 9, wherein the patient achieves a reduction from baseline in the total domain score FAIM.
27. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein the observed difference in response rate between treated and untreated patients in a double-blind, placebo-controlled food challenge of 600 mg allergen is greater than 35%, wherein said response rate is defined as less than or equal to a mild response to a 600 mg oral food challenge.
28. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein by 12 or 24 weeks of treatment, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipase levels do not change by more than 10% compared to baseline levels at the start of treatment.
29. The pharmaceutical composition according to any one of claims 1 to 9, wherein LOU064 is administered in the form of an oral pharmaceutical formulation comprising nano-sized particles of LOU064.
30. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is administered in the form of an oral pharmaceutical formulation comprising nano-sized particles of LOU064 having an average particle size of about 50 nm to about 750 nm as measured by photon correlation spectroscopy.
31. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is administered in the form of an oral pharmaceutical formulation comprising LOU064 and a binder in a weight ratio of about 2:
1.
32. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is administered in the form of an oral pharmaceutical formulation comprising LOU064, a binder and a surfactant in a weight ratio of about 2:1:0.
08.
33. The pharmaceutical composition of claims 1-9, wherein LOU064 is administered in the form of an oral pharmaceutical formulation comprising LOU064 and a binder in a weight ratio of about 1:
1.
34. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is administered in the form of an oral pharmaceutical formulation comprising LOU064, a binder and a surfactant in a weight ratio of about 1:1:0.
05.
35. The pharmaceutical composition of any one of claims 1 to 9, wherein LOU064 is administered in the form of an oral pharmaceutical formulation comprising LOU064, polyvinylpyrrolidone-vinyl acetate copolymer as a binder and sodium lauryl sulfate as a surfactant.
36. When LOU064 is measured at a temperature of about 25° C. and an X-ray wavelength, λ, of 1.5405 Å, it has the following properties: 7.8±0.2°2θ, 9.2±0.2°2θ, 12.0±0.2°2θ, 13.6±0.2°2θ, 15.6±0.2°2θ, 16.0±0.2°2θ, 17.8±0.2°2θ, 18.3±0.2°2θ, 18.7±0.2°2θ, 19.2±0.2°2θ, 19.9±0.2°2θ, 22.1±0.2°2θ, 10. The pharmaceutical composition of any one of claims 1 to 9, wherein the crystalline form of the anhydrous free base is characterized by an X-ray powder diffraction pattern including one or more representative peaks at 2θ selected from the group consisting of 23.4±0.2 degrees 2θ, 23.9±0.2 degrees 2θ, 24.8±0.2 degrees 2θ, 25.2±0.2 degrees 2θ, 25.5±0.2 degrees 2θ, 27.2±0.2 degrees 2θ, and 29.6±0.2 degrees 2θ.
37. 1. Use of LOU064 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for use in the treatment or prevention of an IgE-induced allergic reaction, comprising: The use wherein the medicament is administered to the patient for more than six months.
Citation Information
Patent Citations
Methods of treating asthma using a bruton's tyrosine kinase inhibitor
WO2020234780A1
